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Type I interferons (IFNs) are expressed by many cell types following viral and bacterial 
infections, and induce downstream IFN-stimulated genes (ISGs), such as anti-viral genes. 
Tightly controlled up-regulation of tonic type I IFN signaling is required to mediate host 
cell responses to pathogens and restrain inflammation under homeostatic conditions. 
Therefore, understanding the mechanism of type I IFN induction in immune response is 
very important. Enhancement of type I IFN responses in virus-challenged fibroblasts and 
dendritic cells is mediated by well-defined pathways, but the mechanisms underpinning 
macrophage IFN-β responses to bacterial lipopolysaccharide remain unclear. In 
fibroblasts and dendritic cells, type I IFNs have been demonstrated to induce further type 
I IFN expression via an autocrine/paracrine positive feedback loop mediated by particular 
interferon regulatory factors (IRFs). In macrophages, autocrine/paracrine type I IFN 
signaling have been shown to be important for the induction of some chemokines, but the 
molecular mechanisms mediating the amplification of IFN-β expression itself are less 
clear. Here we report that that autocrine/paracrine type I IFN signaling is required for 
efficient IFN-β responses in LPS-challenged macrophages but not in other myeloid-
lineage antigen presenting cells such as dendritic cells. On the other hand, IL-27p28 a 
subunit of IL-27 cytokine known to exert diverse immunomodulatory effects on 
lymphocyte activation and function, was found to be required for amplification of the 
macrophage IFN-β response. Biochemical analyses revealed that LPS-induced STAT1 
tyrosine phosphorylation is significantly attenuated but not completely abolished in IL-
27p28 deficient macrophages. Reduced IFN-β production is reflected in varying degrees 
of reduction in the levels of induction of several interferon stimulated genes (ISGs), some 
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of them such as CXCL10 in turn required for restraining inflammatory responses to 
endotoxin exposure.  
Our data further show that IL-27p28 maintained high-level expression of basal 
IRF7 in resting macrophages via regulation of constitutive type I IFN signaling. Under 
homeostatic conditions, resting macrophages exhibit constitutive IL-27p28 mediate IFN-
β by promoting a transcription factor Pu.1 binding directly on IFN-β gene promoter. 
Upon challenge of endotoxin, the constitutive and inducible IRF7 subsequently 
synergized with IRF3 to augment the IFN-β response in macrophages but not dendritic 
cells. Accordingly, Accordingly, Irf7–/– mice exhibited substantially reduced serum levels 
of type I IFN and were resistant to lethal endotoxin shock.  
Only macrophages, but not dendritic cells deficient in IL-27p28 exhibited 
defective IFN-β production, impaired IL-10 synthesis, and disrupted STAT3-mediated 
anti-inflammatory responses. Interestingly, a very low dosage of exogenous IFN-β 
sufficiently increases IRF7 level in IL-27p28-deficient macrophages prior to the LPS 
stimulation and subsequently rescue the defective LPS induced IFN-β. Similarly, 
impaired IL-10 expression in BMMs lacking IL-27p28 can be also restored by the 
addition of exogenous IFN-β, resulting in the restoration of IL-10-mediated suppression 
of the pro-inflammatory cytokines TNF-α, IL-6 and IL-12. In summary, our data suggest 
that a novel IL-27p28-IFNβ signaling axis marshals constitutively expressed IRF7 into 
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1.1 Immune response 
The immune defenses of the body are subdivided into two categories; innate response 
which are nonspecific and acquired response which are specific. Despite their 
differences, innate and adaptive responses are highly interdependent, this thesis will 
present some of the vital associations between the two responses, namely, antigen 
presenting cells (APC) and type I interferon (IFN). 
Innate immune response depends on interrelated defense mechanisms which 
respond to antigens such as abnormal or foreign bodies like cells, pathogens. The 
responses are nonspecific and also not dependent on previous exposure to similar 
antigens. They include physical barriers to infection, inflammation, and complement 
activation. This thesis will focus on describing the inflammation process featuring how 
the APC and the cytokines they produce, such as type I IFN make significant impacts in 
immunity. The transcriptional regulation of the cytokines and the downstream cascade of 
cytokines networking will be described in further detail. 
 
1.2 Inflammation 
Inflammation is a series of local cellular and vascular responses to tissue damage or 
infection which accelerates the destruction and phagocytic clearance of invading 
organisms or debris in the complexity of losing cellular and tissue homeostasis, 
disrupting many important normal physiological processes1. Macrophages are known as 
antigen presenting cells and their major role is to be the first line of defense in the innate 
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immunity. Macrophages in the vicinity of the site of foreign invasion are activated to 
become more mobile and phagocytically active for the antigenic challenge. On the site, 
damaged and infected cells release chemicals to attract these macrophages, directing 
them towards the damaged area in a process known as chemotaxis. Furthermore, 
chemotaxis continually recruits reinforcements such as neutrophils and monocytes from 
the blood circulation to complement the reaction of local macrophages. 
1.2.1 Macrophages in inflammation  
The congregation of large numbers of phagocytes such as macrophages and neutrophils 
within a tissue is the typical histological hallmark of acute inflammation. During this 
process, other than the best known macrophages chemoattratants like macrophage 
inflammatory protein 1 (MIP-1/CCL3) and monocyte chemoattractant protein 1 (MCP-
1/CCL2)2, some other molecules for examples bradykinin, serotonin, prostaglandins and 
their family members or similar compounds also play a key role to increase blood flow 
caused by dilatation of local blood vessels and increase in capillary permeability 
promoting diapedesis, facilitating the acute inflammation repertoire.  
The cascade effects of cytokines, chemokines and effective molecules that 
secreted by inflammatory cells become even elusive and develop multi-layers of crosstalk 
in the later phase which is the systemic effects of inflammation, resulting in the increase 
of body temperature and white blood cell count (leukocytosis)3. Following on, the antigen 
presenting cells, particularly dendritic cells (DCs) start to initiate the transition from the 
innate immunity to the adaptive immunity. Macrophages and DCs are crucial mediators 
of the inflammatory response, and Toll-like receptors (TLRs) are the best-characterized 
inducers of acute inflammation in the field which this thesis is going to focus on. 
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 1.2.1 Dendritic cells in inflammation  
DCs form networks of cells along body surfaces, often intimately associated with the 
tissues that are physically in contact with the foreign environment, such as the skin and 
the epithelium of the nose, lungs, stomach, intestines and many other. DCs serve as a 
principal reservoir of antigens in the immune system. Once foreign proteins are 
introduced in situ, dendritic cells capture them and process them to be antigens; 
subsequently they migrate to lymph node/lymphoid tissues to seek contact with T cell 
whom they present the antigens to. During this DCs homing process, CCR7 that 
expressed on DCs and the corresponding chemokines, CCL9 and 21 in the lymph node/ 
lymphatics are likely involved4. 
Through the interaction between co-stimulatory molecules like the B7 family of 
the dendritic cell with CD28 present on the lymphocyte and the cytokines that provided 
by DCs, naive CD4+ T cells differentiate towards a Th1 phenotype that is the effector 
immune cells to involve in the immunity and inflammation. The ultimate result is 
initiation and activation of the immune system for attack specifically against the antigens 
which the dendritic cell uptake on the site and present on the surface. However, there are 
differences in the cytokines produced depending on the type of dendritic cell. The 
plasmacytoid DCs has the ability to produce huge amounts of type-1 IFN's, which recruit 






1.2.3 Complementary but unique roles of APCs in inflammatory response 
In short, there is similarity and difference between macrophages and DCs in term of their 
characteristic and the roles in inflammation and immune response, however, they both are 
indispensable and often synergize each other contribution. For example, in virus 
infection, macrophages and DCs play a very different role in term of Type I interferons 
(IFNs) which are widely known as critical components of innate immunity and host 
protection against viruses6. Macrophages are abundant in host tissues, produce large 
quantities of type I IFN upon phagocytosis of viral particles, and represent key mediators 
of host protection against viruses7,8. There is one study reported that macrophage 
depletion is sufficient to decrease the type I IFN response to vesicular stomatitis virus 
(VSV) and led to increased mortality of infected animals, whereas depletion of 
plasmacytoid dendritic cells (pDCs) did not alter host survival 9. Indeed, several studies 
have now reported that macrophages exhibit greater potential for virus-induced type I 
IFN synthesis than either fibroblasts or conventional dendritic cells (cDCs)10,11. The 
molecular basis for these lineage-specific differences in IFN responses are not well 
understood, although it is possible that macrophages express higher levels of molecules 
involved in the activation of IFN signaling pathways12,13 and enhance the transcriptional 
regulation of it. 
 
1.3 Transcriptional regulation of inflammatory response 
The complexity of the inflammatory response requires many precise and accurate 
programmes to control coordinately depending on the situations. This can be only 
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achieved through multiple mechanisms that operate at different levels, including 
alterations in the composition of immune cells in situ, changes in cell responsiveness to 
inflammatory stimuli, regulation of signalling pathways and control at the level of gene 
expression. In short, control and regulation of inflammation by immune system ought to 
be executed in a balanced combination of spatial, magnitude and temporal approach. The 
mechanisms that regulate inflammatory responses can be divided into cell-specific, 
signal-specific and gene-specific mechanisms. Therefore, like many other studies, this 
thesis will attempt to address any questions from all these three aspects.  
 
1.3.1 Different layers of transcriptional regulation in inflammatory response 
Cell-specific mechanisms operate at the level of different cell types, and include 
regulation of their recruitment and activation. Generally, different cell have their own 
expertise and roles in different setting upon different challenges. Signal-specific 
mechanisms operate at the level of signaling pathways: for example, by deactivating the 
key transcription factor (TF) nuclear factor-κB (NF-κB) or activator protein 1 (AP-1) as 
part of the negative feedback mechanism14,15. Last but not least, gene-specific 
mechanisms operate at the level of individual genes and gene subsets. For example, 
interleukin-10 (IL-10) and many nuclear receptors negatively regulate the transcription of 
specific subsets of inflammatory genes. As such, we can easily conclude that gene-
specific mechanisms are particularly well suited to provide functional specificity in an 
inflammatory response. So, understanding the transcriptional regulation of some specific 
genes/proteins in a cell-type specific setting is very important to answer some puzzles in 
the complexity of inflammation. 
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Consistent with the complexity of the response, induction of a transcriptional 
response is generally orchestrated by many molecules from receptors to adaptors, 
ultimately resulting with transcription factors affecting the gene locus. In terms of 
positive regulation, for example, the synergy between both adaptors, myeloid 
differentiation primary response gene 88 (Myd88) and TIR-domain-containing adapter-
inducing interferon-β (Trif)  can result in up to 100 folds stronger induction of IL-10 
compared to if only either one adaptor was present16. Through Myd88 and Trif, the signal 
is passed on to numerous transcription family members, including specificity protein 
(Sp), signal transducers and activators of transcription (STAT), interferon regulatory 
factors (IRF), activator protein (AP), cAMP response element binding protein (CREB), 
CCATT enhancer/binding protein (C/EBP), c-musculoaponeurotic fibrosarcoma factor 
(c-MAF), and nuclear factor κ-B (NF-κB). These transcription factors have all been 
characterized as essential factors in IL-10 regulation17. IL-10 has also been described to 
display anti-inflammatory properties18, therefore, all the above mentioned factors will 
have to be kept in check via the establishment of a regulatory feedback loop in order to 
control inflammation by simultaneously promoting release of anti-inflammatory proteins 
and preventing excessive release of proinflammatory proteins like interleukin-6 (IL-6), 
interleukin-12 (IL-12).  
This is only one simple example of the importance and significance of 
transcriptional regulation in inflammation and immune response. Recent studies have 
provided evidence of many other layers of mechanism making significant contribution to 
this regulation including long non-coding RNAs (lncRNAs)19, microRNAs20 , Chromatin 
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Remodeling21, Histone modification22 and many others which will not be addressed 
extensively herein. 
 
1.4 Type I Interferon 
Previous studies in our lab have showed that macrophages produce a more rapid and 
robust Type I IFN response against pathogen challenge via the activation of specific 
transcription factors and their subsequent interactions23. Given the fact that type I IFN has 
been recognized in the field as one of the central regulators that bridge innate and 
adaptive immunity24, we aim to improve our current knowledge of the regulation and 
functions of Interferon beta (IFN-β) in inflammatory cells, particularly in APCs to give 
an impactful finding for the complexity of inflammation involved by type I IFN and its 
physiological and patho-physiological significance.   
Interferons (IFNs) are glycoproteins first discovered more than 50 years ago to 
“interfere” with influenza virus replication in chick chorio-allantoic membranes25. 
Currently, about 10 mammalian members of the IFN family have been identified, of 
which seven are found in humans26. They are classified into type I IFNs (IFN-α, -β, -ω, -ε 
and -κ), type II IFNs (IFN-γ), and type III IFNs (IFN-λ, also known as IL-28/29)27. Since 
the initial discovery of their antiviral activity, IFNs have been demonstrated to be multi-
functional cytokines exerting additional cellular effects, including anti-angiogenic and 
anti-proliferative (hence anti-tumor), and anti-inflammatory properties. These have 
permitted their clinical use as therapeutics in viral infections (e.g. IFN-α2 for treatment of 
Hepatitis C Virus infections), in oncology (e.g. IFN-α2 for treatment of hairy cell 




IFN-β has been implicated in many human diseases related to inflammation, including 
autoimmune diseases and various cancers. In 1993, IFN-β1a and IFN-β1b were approved 
by the United States Food and Drug Administration for the treatment of relapsing-
remitting multiple sclerosis (MS)29, although the mechanisms and efficacy of this 
treatment are still hotly debated and intensely controversial30,31. Recently, a 21-year 
follow-up study provided important new evidence that IFN-β1b reduced all-cause 
mortality in MS patients32. Another potential clinical application of type I IFNs recently 
emerged in prevention of Graft-versus-Host Disease (GVHD) and improvement of Graft-
versus-Leukemia (GVL) in allogeneic hematopoietic stem cell transplantation33. IFN-β 
exerts a wide range of biological activities in the human immune system, such as  
initiating the synthesis of anti-viral proteins, promoting cytotoxic activity, and driving the 
differentiation and maturation of certain leukocytes32,34-37. 
Numerous clinical and laboratory findings have shed new light on the roles of 
IFN-β in human health and disease, presenting new opportunities to develop a better 
understanding of the actions of IFN-β in immunological disorders. This thesis will aim to 
expand the current knowledge of the regulation and functions of IFN-β in inflammatory 
cells, including human monocytes and dendritic cells (DCs), which sit at the junction of 
innate and adaptive immunity. The key roles of IFN-β in the development and function of 
innate and adaptive immune cells will be introduced, followed by the description of the 





1.4.2 IFN-β of Antigen Presenting Cells 
Although typically elicited by viruses, type I IFN can also be induced by bacterial 
infections38,39. Regardless of the type of pathogen encountered, macrophages are early 
producers of IFN-β that primes other macrophages and nearby immune cells to secrete a 
repertoire of pro-inflammatory cytokines40-42. IFN-β plays a pivotal role in macrophages 
by synergizing with signaling pathways downstream of patterns recognition receptors 
(PRRs) including Toll-like receptors (TLRs) to induce optimal production of pro-
inflammatory cytokines. IFN-β synergy with PRR signaling can be either beneficial or 
deleterious to the host depending on the setting43. The contrasting anti-inflammatory role 
of IFN-β has also been described in several reports, IFN-β could either increase 
resistance or susceptibility44 to the invading pathogen, and increase either survival rate45 
or lethality46 post infection. For example, in infection with Listeria monocytogenes44,47,48 
or Tropheryma whipplei49, excessive type I IFN production may be detrimental to the 
host.  
 
1.4.2.1 IFN-β of macrophages in immune response 
Macrophages detect intracellular pathogen-associated molecular patterns (PAMPs) via 
internalization into endosomal compartments50 followed by degradation in phago-
lysosomes. The anti-microbial activities of macrophages are crucial to host defense40,51, 
and recent infection studies using viruses and L. monocytogenes have unveiled several 
novel cytosolic PRRs, in addition to the more established TLRs, RIG-I, Mda-5 and 




1.4.2.1.1 PAMPs in macrophages that trigger IFN-β and the regulation  
Nucleotide-binding oligomerization domain (NOD) proteins comprise a family of NOD-
like receptors (NLRs) – intracellular PRRs that recognize only peptidoglycan (PGN) 
degradation products such as muramyl dipeptides (MDP) and muramyl tripeptides 
(MTP). Herskovits and colleagues showed that NOD2 is indispensable for the optimal 
induction of IFN-β in macrophages after phagocytosis and degradation of L. 
monocytogenes51. Recently, two other groups discovered that Mycobacterium 
tuberculosis and respiratory syncytial virus (RSV) stimulate the cytosolic NOD2 pathway 
to initiate type I IFN expression in a TANK-binding kinase 1 (TBK1)-IRF5-dependent 
fashion in the case of bacterial PGN52 or via a MAVS-IRF3-mediated pathway for single-
stranded RNA (ssRNA)57. 
DNA-dependent activator of IRFs (DAI, also known as DLM-1 or ZBP1) is a 
cytosolic DNA sensor and activator of the innate immune response53. Intracellular DAI 
facilitates B-DNA (B form DNA)-mediated induction of IFN-β in a TBK1-IRF3-
dependent manner. While Wang et al. have reported that silencing of DAI mRNA 
expression inhibits IFN-β activation58, another independent group have claimed that DAI 
deficiency does not affect IFN-β production59. However, this discrepancy could be 
possibly due to the different cell types used in these separate experiments. 
Another new DNA sensor recently discovered in macrophages as well as DCs 
is ‘Absent in melanoma 2’ (Aim2) which was detected by screening for proteins that 
interact with double-stranded DNA (dsDNA) and can be induced by IFN-β60. Aim2 
localizes to the cell cytoplasm and binds dsDNA via its DNA binding HIN200 domain 
(HIN200 is a 200 amino-acid domain that a group of proteins contain that describing their 
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hemopoietic expression, IFN-induction, nuclear localization61), thus sensing DNA and 
inducing the production of pro-inflammatory cytokines, especially IL-1β, as it forms a 
functional inflammasome complex together with ASC and caspase-154. IFI16 is another 
pyrin and HIN domain (PYHIN)-containing protein which functions as an innate sensor 
for intracellular DNA, and it has been proposed that PYHIN proteins may represent a 
new family of innate DNA sensors, named AIM2-like receptors (ALRs)62. 
In addition, Yang et al.56 identified a novel PRR that can detect both dsDNA and 
dsRNA to trigger type I IFN production in macrophages challenged with vesicular 
stomatitis virus (VSV) and L. monocytogenes. LRRFIP1 promoted the activation of 
interaction partner β-catenin, which enhanced IFN-β expression by binding to the C-
terminal domain of IRF3 and recruiting the histone acetyltransferase p300 to the IFNB 
enhanceosome56. 
 
1.4.2.1.2 Biological significance of macrophages produced IFN-β in immune 
response 
Interestingly, NOD263, RIG-I64 and Aim254,60 are induced by IFN-β itself, suggesting that 
they are engaged in a positive feedback loop with this cytokine. Upon pathogen 
stimulation, PRRs activate IFN-β secretion into the extracellular milieu where it binds to 
type I IFN receptors (IFNARs) on the secreting cell, as well as on neighboring cells, thus 
driving an autocrine/paracrine loop that up-regulates a series of genes including NOD263, 
RIG-I64 and Aim254,60. This sequence of events heightens immune surveillance in the 
local micro-environment and strengthens cellular resistance to infection. 
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A number of the cytosolic PRRs have been implicated in inflammasome complex 
formation and inflammatory caspase-1 activation. Intriguingly, type I IFN signaling 
downstream of the IFNAR was reported to inhibit NLRP1 and NLRP3 inflammasome 
activation, which reduced IL-1β production in mouse and human monocyte/macrophages 
pre-treated with IFN-β and then challenged with lipopolysaccharide (LPS) and 
adjuvant65. This study also demonstrated that type I IFN signaling induced IL-10 and 
reduced pro-IL-1β synthesis65, indicating that IFN-β treatment can suppress both pro-IL-
1β expression and cleavage to bioactive IL-1β65. 
Macrophage-derived cytokines including IFN-β play a key role in the 
differentiation of immune effector cells, which effectively bridges the innate and adaptive 
immune responses66,67. Antigen-presenting cells (APCs) like macrophages and DCs 
produce both type I and type II IFNs, and promote MHC class I and II expression, which 
drives the development of CD8+ and CD4+ T cell responses68. As described below, IFN-
β production by DCs helps to establish a critical link between innate and adaptive 
immunity which is required for the effective clearance of pathogens. 
 
1.4.2.2 IFN-β of DCs in immune response 
DCs are archetypal sentinel cells which detect pathogens and elicit immune responses43. 
DCs have long been known to produce type I IFN in response to viruses, purified 
bacterial DNA and synthetic prokaryotic oligonucleotides69, but until comparatively 
recently, only macrophages were thought to be capable of responding to whole bacteria70. 
However, a novel role for DCs in innate immunity has recently emerged with the report 
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that conventional DCs (cDCs), but not plasmacytoid DCs (pDCs) or macrophages, were 
able to produce large amounts of IFN-β following bacterial degradation in 
phagolysosomes, which required TLR7, MyD88 and IRF170. 
The intriguing realization that APCs are the main sources of IFN-β during 
infection41,71,72 underscores the pivotal role of IFN-β in adaptive immunity73. Using a 
single cell visualization method, Scheu et al. characterized the relative contributions of 
each cell type to in vivo IFN-β production in response to different stimuli71. IFN-β 
induces DC up-regulation of MHC class I molecules74, enhances DC maturation and 
activation75,76, and ultimately promotes Th1 responses77,78. Type I IFN is the major driver 
of DC maturation into immuno-stimulatory cells and is required for the generation of 
CD4+ Th1 cell responses36. The high levels of type I IFNs secreted by pDCs can activate 
CD8+ T cells and support cross-presentation while also enhancing CD4+ Th1 
development and restricting differentiation toward Th2 and Th1779. 
 
1.4.2.2.1 Application of IFN-β on DCs  
The immuno-modulatory effects of IFN-β on DC-mediated T cell responses provide 
possible targets for the development of novel therapies. DC vaccination strategies involve 
activating DCs with immunogenic antigens in vitro to boost T cell responses, followed by 
re-infusion of the activated cells to generate protective immunity to viral and bacterial 
infections, and cancers. However, optimizing the delivery and presentation of DCs 
remains a difficult challenge. Surprisingly, several recent studies have announced 
unprecedented efficacy of DC-based vaccines in the presence of type I IFN, which may 
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accentuate DC activation36. TLR7 activation enhanced the ability of DCs to acquire 
antigens during type I IFN-dependent migration to draining lymph nodes80. In a separate 
investigation, the TLR agonists poly(I:C) and LPS together with type I and II IFNs 
generated mature DCs with high migratory capacity and IL-12 production 81. Type I IFN 
is now therefore recognized as a vaccine adjuvant, and it may be possible to predict 
vaccine efficacy by assessing the level of type I IFN induced82. 
 
1.5 IFN-β bridge the link from Innate Immunity to Adaptive Immunity 
The ability of IFN-β to shape the adaptive immune response by activating and priming T 
cells is well-recognized. Numerous studies have confirmed that the timing of IFN-β 
exposure determines the positive or negative effect on Th1 polarization 83, which is 
influenced by distinct Signal Transducers and Activators of Transcription (STAT) 
transcription factors that are recruited upon type I IFN activation in DCs 84. Type I IFN 
can therefore influence T cell activation and differentiation directly, but can also 
modulate T cell response through effects on DCs.  
Although the mechanism of action of IFN-β therapy for relapsing-remitting MS 
remains unclear at this time, effects on T cell homeostasis seem likely to contribute to the 
efficacy of this intervention. IFN-β ameliorates Th1 cell pathologies in MS patients by 
abrogating the pro-inflammatory properties of IFN-γ and IL-1285. IFN-β also restores the 
function of regulatory T cells in MS patients by increasing the frequency and inhibitory 
capacity of these cells86,87. In addition, IL-10/IL-27-producing CD4+ T cells are 
augmented after IFN-β therapy, possibly amplifying their immunosuppressive activity 
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and constraining Th17 cell expansion87,88. In contrast, a recent report indicated that IL-10 
production is unaltered and that IL-17 levels are decreased upon IFN-β treatment, leading 
the authors to conclude that IFN-β is pro-inflammatory in Th17-induced experimental 
autoimmune encephalomyelitis89. These data indicate that care must be exercised when 
administering IFN-β therapy in the clinic before determining the disease subtype (Th1 
versus Th17)89. 
The therapeutic role of IFN-α in GVHD and GVL after allogeneic bone marrow 
transplantation has been known for decades90,91, especially in relapse of chronic myeloid 
leukemia after bone marrow transplantation92. However, the mechanisms of action 
remain obscure, and the application of type I IFN in this setting remains 
controversial93,94. A study by Robb et al. suggested that the efficacy of type I IFN in 
protecting patients from GVHD and GVL can be attributed to the suppression of donor 
CD4+ T cell proliferation and differentiation33. In contrast, CD8+ T cell-dependent 
GVHD and GVL responses were enhanced by the pleiotropic effects of type I IFN. 
Further investigations will be necessary to address this apparent dichotomy and to clarify 
the complex role of type I IFN in this context. 
Type I IFN is able to induce long-lived antibody production and isotype class 
switching by inducing activation and differentiation of plasma cells and memory B 
cells73,95. Type I IFN enhances proliferation and prevents apoptosis of primary B cells, 
even in the absence of mitogenic stimuli96. and generally enhances B cell development 
and antibody production97. 
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A classical study published in 2002 demonstrated that IFN-α/β increased survival 
and decreased apoptosis of B cells, as well as amplifying B cell activation and antibody 
responses upon B cell receptor stimulation98. IFN-α/β secreted by virus-activated pDCs 
were then shown to induce the differentiation of CD40-activated B cells into antibody-
secreting plasma cells99. In line with these findings, increasing evidence now links type I 
IFN with B cell production of auto-antibodies and increased risk of autoimmune diseases, 
particularly systemic lupus erythematosus100-102. The multiple roles of IFN-β in different 
cells of the immune system are summarized in the Fig. 1.  
In short, IFN-β produced (mainly by APC) in the innate immunity serve as a 
conduit that initiate the immuno-repertoire of adaptive immunity in order to reinforce the 
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Fig.1. The role of IFN-β in different immune cells. 
Aside from the antiviral effect, IFN-β increase the ability and efficiency of antigen 
presenting in APC and play key roles in different immune cells in many different ways 
including maturation, differentiation, cytokines release, polarization. 
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Fig.2. IFN-β is a central regulator of innate and adaptive immunity.  
IFN-β enhances DC maturation and activation. Macrophage- and DC-derived IFN-β 
promotes Th1 responses and activates CD8+ T cells, as well as enhances CD4+ Th1 
development while restricting differentiation toward Th2 and Th17. It also induces 
antibody production and isotype class switching by enhancing B cell development and 
differentiation into plasma cells. Once the pathogens/alien bodies invade the immune 
system, the first line defender macrophages encounter them and release the first wave of 
IFN-β which stimulate macrophages itself as well as DC to produce even more IFN-β in a 
autrocrine and paracrine manners. Subsequently, the IFN-β that produce in the Innate 
Immunity also act on T and B cells that trigger the adaptive immunity in which as a 





1.6 Activation of IFN-β 
As outlined above, IFN-β can directly and indirectly influence the functions of a plethora 
of innate and adaptive immune cells, including monocytes, macrophages, DCs, T cells 
and B cells. Type I IFN production can be stimulated by pathogen ligands from diverse 
microorganisms103, among which bacterial LPS and viruses are two of the most well-
studied. Type I IFN has been shown to be critical for the control of bacterial, viral and 
even protozoan infections 104. The classical IFN-β signaling pathway consists of 
membrane-associated or cytosolic receptors, adaptor proteins in the cytosol, and 
transcription factors in the nucleus (Fig. 3).  
TLR receptors can sense a variety of bacterial and viral ligands which include 
bacterial LPS (TLR4), peptidoglycan (TLR2), Pam3CSK4 (TLR1/2), dsRNA and 





Fig.3. TLR4 induced IFN-β signaling pathway.  
(a) Current opinion about the signalling pathway of LPS induced IFN-β and ISGs 
(Adapted from Honda et al., 2006 Immunity)in macrophages. (b) Recognition by various 
Toll-like receptors (TLRs) activates the MyD88/TIRAP and TRIF/TRAM signaling 
pathways. The common adaptor protein pair MyD88/TIRAP mediates the activation of 
transcription factor NF-κB to induce rapid expression of pro-inflammatory cytokines 
including tumor necrosis factor (TNF), whereas the TRIF/TRAM pathway is crucial for 
the activation of IRF3 and induction of type I IFN responses (Adapted from Takeuchi et 






1.6.1 Activation of IFN-β by viruses 
Type I IFNs have long been known to be expressed ubiquitously by many cell types, 
including immune cells (e.g. macrophages and dendritic cells (DCs)) and non-immune 
cells (e.g. fibroblasts), in response to viral infections106. This occurs following the 
recognition of viral components or pathogen-associated molecular patterns (PAMPs) by 
pattern recognition receptors (PRRs), including cell surface and endosomal Toll-like 
receptors (TLRs) as well as cytosolic PRRs. When viral infection, IFN-β binds to 
IFNARs (autocrine/paracrine/systemic) on the surface of cells to trigger the expression of 
a large number of anti-viral genes107. dsRNA is a PAMP derived from viruses which can 
be detected by TLR3 to induce activation of TRIF, which is also a key mediator of the 
LPS response pathway. TRIF has been shown to bind to TLR3 by co-
immunoprecipitation108, and the same methodology was employed to prove that the N-
terminal domain of TRIF interacts with TBK1 and TRAF6, while the C-terminal domain 
of TRIF binds to the kinase RIP1109. Furthermore, it was shown that TBK1 physically 
interacts with IRF3 and the macrophages from TBK1 knockout mouse exhibit defective 
IRF3 activation and IFN-β transcription110. In this virus infection model, TBK1 and IKKi 
phosphorylated IRF3, which either homodimerizes or heterodimerizes with IRF7, 
translocates into the nucleus, and binds to the IFN-β promoter region to up-regulate IFN-
β expression110. IRF7 is another member of the IRF family of transcription factors that 
can be activated upon virus infection111 and produced by ligation of IFN-β and IFNAR112. 
It was previously reported that the response to myxoma virus infection in mouse pDCs is 
dependent on IRF7 but not on IRF3113. Latent IRF7 is localized in the cytoplasm in virus-
naïve cells, but becomes phosphorylated by TBK1/IKKi and forms a homodimer upon 
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virus infection, followed by translocation into the nucleus to establish the IFN-β 
enhanceosome together with IRF3 and other transcription factors. 
 
1.6.2 IFN-β induction of different viruses-infected cells 
In general, not limited by TLR3 pathway, basically most of the TLR activation by 
“danger” signals leads to the initiation of intracellular signal transduction cascades, 
through MyD88-dependent or TRIF-dependent pathways and mediated by interferon 
regulatory factors (IRFs), to culminate in the induction of pro-inflammatory cytokines 
and chemokines and/or type I IFNs114. In plasmacytoid DCs (pDCs), the prototypical 
“IFN-producing cells” (IPCs), the MyD88-IRF7 pathway mediates the induction of high 
levels of IFN-α and IFN-β following activation of TLR9 by CpG-A DNA115,116. 
However, in conventional DCs (cDCs), IFN-β induction following recognition of CpG-B 
DNA by TLR9 is mediated by the MyD88-IRF1 pathway117,118. This exemplifies cell-
type specific signaling pathways leading to type I IFN induction.  
 
1.6.2.1 IRF7 and IRF3 dependent IFN-β induction of different viruses-infected cells 
In fibroblasts, the “classical pathway” involves the sensing of viral infection by the 
cytosolic PRRs RIG-I and MDA-5. This activates the transcription factors IRF3 and 
IRF7, which induce the early phase production of primary response genes and small 
amounts of IFN-β. The secreted IFN-β binds to type I IFN receptors (IFNARs) on the 
same cell or on neighboring cells to trigger downstream JAK-STAT signaling pathways 
and up-regulation of IRF7 expression, which upon simultaneous activation induces the 
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later phase production of large amounts of type I IFNs and secondary response genes119-
123. This constitutes a type I IFN-dependent, IRF7-mediated autocrine/paracrine positive 
feedback loop that amplifies the production of type I IFNs and the expression of IFN-
stimulated genes (ISGs), including antiviral genes that confer the establishment of an 
antiviral state106. Upon virus infection, latent IRF7 in the cytoplasm is phosphorylated by 
TBK1/IKKi and forms a homodimer, followed by translocation into the nucleus to 
establish the IFN-β enhanceosome together with IRF3 and other transcription factors 
(Fig. 4). 
Extensive studies on the chromatin structure and promoter architecture of the 
IFNB gene have revealed that IFN-β transcriptional activation requires the enhancer 
region located immediately upstream of the core promoter. Virus infection results in the 
coordinate activation of transcription factors that assemble on this IFN-β enhancer region. 
NF-κB, ATF-2/c-Jun, PU.1 and IRFs have been identified as possessing cognate binding 
sites on the IFN-β promoter region, which regulate IFN-β mRNA transcription: the 
binding of these regulators is concentrated on ~(-100)bp of the IFN-β genomic locus124,125 
(Fig. 4). 
 
1.6.2.2 Other TFs dependent IFN-β induction of different viruses-infected cells 
Type I IFN production differs in magnitude and kinetics between different cell 
types. Other groups have previously reported the initiation of IFN-β transcription at 6 
hours post-virus infection in HeLa cells126, while our group has observed early expression 
of IFN-β in human blood monocytes within only 1-2h of exposure to Sendai Virus127. 
23 
 
This disparity raised the possibility that distinct myeloid-specific transcription factor(s) 
may be involved in the rapid induction of IFN-β in monocytes compared with non-
myeloid cell types127. We determined that this monocyte-exclusive phenomenon can be 
attributed to the constitutive binding of the other transcription factors IRF8 and PU.1 to 
the PRDII motif of the IFN-β promoter, thus creating a preformed activation complex on 
the IFN-β promoter which facilitates rapid recruitment of IRF3 via direct interactions 
with IRF8 (Fig. 4)127. In contrast to other ubiquitously expressed IRF family members, 
IRF8 is expressed only in myeloid cells. IRF8 (also known as interferon consensus 
sequence binding protein; ICSBP) is a transcription factor protein originally isolated 
based on recognition of the promoter region of the H-2LD MHC class I gene128. siRNA-
mediated knockdown of IRF8 in monocytes dramatically blocked SeV- and LPS-induced 
IFN-β transcription, while ectopic expression of IRF8 in mouse 32D (IRF8-/-) cells 
successfully rescued SeV-induced IFN-β transcription127. Through these and other 
experiments, we have been able to demonstrate that IRF8 directly synergizes with IRF3 
in monocytes to facilitate faster IFN-β transcription after pathogenic stimulation (Fig. 4). 
This published work is one of the initiatives for us to examine the molecular synergize in 
antigen-presenting-cells for the optimal level of the IFN-β upon LPS stimulation which 
showcased in this thesis. 
Different patterns of type I IFN production can be induced by different PRRs in 
response to viral infections. For example, West Nile virus activates TLR3129, whereas 
vesicular stomatitis virus interacts with TLR7, and herpes simplex virus (HSV)-1 and 
HSV-2 use TLR9 to activate type I IFN signaling130-132. Besides membrane-associated 
TLRs, members of the cytosolic RLR family have also been found to be stimulated by 
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viruses. For instance, retinoic acid inducible gene-I (RIG-I) is employed by Newcastle 
disease virus133, while melanoma differentiation associated gene-5 (Mda-5) is activated 
by Dengue virus134. This may be due to the different infection strategies used: while some 
viruses bind to cell membranes, other viruses gain entry into the cytosol through fusion of 




 Fig.4. Models of the IFN-b enhanceosome in non-myeloid and myeloid cells.  
(a) Assembly of transcription factors on the IFN-b enhanceosome as determined from 
crystal structures. ATF-2/c-Jun, IRF3/IRF7, and NF-κB bind cooperatively to the IFN-b 
enhancer: ATF-2/c-Jun in complex with two IRF molecules on positive regulatory 
domain (PRD) IV-PRDIII, and NF-κB in complex with two IRF molecules on the PRDI 
and PRDII regions of the enhancer. (b) Our lab previously determined that rapid 
induction of IFN-β in monocytes can be attributed to the constitutive binding of IRF8 and 
PU.1 to the ETS/IRF composite element (EICE) motif of the IFN-b promoter. Putative 
IRF3 and IRF8 binding sites are underlined. The potential involvement of other 
transcription factors at the ETS/IRF response element (EIRE) motif within the PRDIII 
region as well as the PRDIV region in monocytes remains to be confirmed. In this study, 




1.6.3 Constitutive IFN-β 
It has been proposed that a constitutive low level of IFN-α/β expression and weak IFN-
α/β signaling in uninfected cells contributes to the massive and effective type I IFN 
response upon encounter with viral infection136,137. Specifically, constitutive low level of 
IFN-β expression and weak IFN-β signaling is also found to be operational in uninfected 
murine macrophages138. This endogenous IFN-β autocrine loop contributes to a basal 
level of expression of some type I IFN target genes such as STAT1, and “primes” the 
cells for a more dramatic increase in activation of the TRIF-IRF3 pathway leading to 
amplified IFN-β production and ISG expression in response to LPS stimulation138. 
On the other hand, recent studies demonstrate that in healthy animal, the 
commensal microflora provide tonic signals to maintain a basal systemic type I IFN 
response which fine-tunes innate immune responses and maintains homeostasis  
including maintenance of the hematopoietic stem cell (HSC) niche, immune cell function, 
and bone remodeling139-141. In fact, this thesis will introduce how the constitutive IFN-β 
and the autocrine/paracrine positive feedback loop that induced IRF7 in resting state may 
contribute to the full induction of IFN-β when APCs exposed to pathogens.  
 
1.6.4 Activation of IFN-β by LPS 
Apart from viral infections, it is now known that bacteria (e.g. Escherichia coli) and 
bacterial components (e.g. lipopolysaccharide (LPS)) can also induce type I IFN 
production142. One of the most well-characterized mechanisms that occurs in many cell 
types is the LPS-induced type I IFN production via TLR4143. TLR4 is a cell surface 
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receptor that recognizes the lipid A (LPA) moiety of LPS of Gram-negative bacteria in 
conjunction with CD14 and MD2 co-receptors, and signals via two distinct pathways 
dependent on either the MyD88 or  the TRIF adaptor proteins120,143.  
 
1.6.4.1 Current view on LPS induced IFN-β of macrophages 
In macrophages, LPS stimulation of TLR4 induces type I IFNs and downstream ISGs 
predominantly via the TRIF-dependent (MyD88-independent) pathway, which originates 
from endosomal vesicles after receptor endocytosis, through the activation of IRF3 
phosphorylation and nuclear translocation144-147. IFN-β is the primary type I IFN that is 
induced in macrophages following LPS stimulation 138. The MyD88-independent 
pathway leads to type I IFN production, although there is significant cross-talk with the 
MyD88-dependent pathway through NF-κB148. TRIF is a critical mediator in this 
pathway, and TRAM and TBK1 are key adaptor molecules in the cytoplasm. The kinase 
TBK1 phosphorylates transcription factor IRF3110, which then dimerizes and translocates 
into the nucleus to induce IFN-β expression149. IFN-β is secreted into the extracellular 
milieu, where it interacts with IFNAR on the host cell membrane to activate downstream 
JAK-STAT signaling150. The phosphorylation and activation of the kinases JAK1 and 
Tyk2 leads to the phosphorylation and activation of the transcription factors STAT1 and 
STAT2, which results in the formation of transcriptional complexes that bind to specific 
promoter regions of downstream cytokines (known as IFN-stimulated response elements; 
ISREs). STAT1/STAT2 binding to ISREs in the presence of pathogenic stimuli such as 
LPS and Sendai virus (SeV) culminates in the induction of pro-inflammatory cytokines 
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including type I IFNs151. This signaling cascade therefore constitutes a positive-feedback 
loop which amplifies the production of type I IFNs.  
IFN-β is transcribed from a single, intronless gene in human and mouse. Using a 
model of virus-infected human epithelial HeLa cells, Maniatis and colleagues have 
identified the component transcription factors of the IFN-β “enhanceosome”, namely NF-
κB RelA/p50, IRF3/7 and ATF-2/c-Jun, that act at the IFN-β enhancer to activate IFN-β 
transcription152(Fig. 4). On the other hand, in LPS-stimulated human monocytes, we have 
found that, in addition to TRIF-dependent IRF3 activation, constitutive binding of the 
myeloid-specific transcription factor IRF8 to the IFN-β promoter region is also required 
for induction of IFN-β transcription153.  
 
1.6.4.1 Bacteria induced IFN-β production mediated by other PRRs 
TLR4 on the host cell membrane is a well-known sensor of gram negative bacterial 
infections. However, there are emerging reports that the gram negative bacteria 
Francisella tularensis and Salmonella typhimurium activate cytosolic PRRs instead of 
TLR4154-157. It was reported that F. tularensis can activate the caspase-1 inflammasome 
via the intracellular sensor Aim2, and can induce type I IFN and other pro-inflammatory 
cytokines via an as yet unidentified sensor. Aim2 is now acknowledged to function as a 
sensor of undigested viral DNA, synthetic DNA, and DNA derived from killed bacteria 
(presumably released from the phagolysosome), ultimately leading to inflammasome 
activation54. In vitro and in vivo studies have now shown that this inflammasome 
activation is Aim2 and IRF3-dependent158. Although inflammasome activation required 
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an intact type I IFN response, F. tularensis-induced type I IFN production required IRF3 
but was independent of a number of TLRs, RIG-I-like receptors (RLRs) and NLRs 
(including Aim2)158. More research needs to be conducted to unravel this apparently 
complex relationship. Therefore, the aim of this study is to also fill in the gap in this field 
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Fig.5. The summary of pathogen-induced signaling pathway leading to IFN-β induction.  
The summary of pathogen-induced signaling pathway leading to IFN-β induction and 
some studies in mutant mice to elucidate the mechanism/contribution of various 




1.7  Interferon-stimulated genes in inflammatory response 
Type I interferons (IFNs) activate antimicrobial programmes and influence the innate and 
adaptive immune responses. Canonical type I IFN signalling activates the Janus kinase 
(JAK)–signal transducer and activator of transcription (STAT) pathway, and 
transcriptionally induce hundreds of interferon-stimulated genes (ISGs). The major factor 
responsible for ISGs transcriptional activation downstream JAK/STAT is a trimeric c 
omplex consisting of Stat-1, Stat-2 and IRF-9, collectively termed ISGF3159. 
Translocated ISGF3 complex binds to the IFN-stimulated response elements (ISREs) via 
the IRF-9 DNA binding domain, and activates transcription160. The functions of ISGs are 
diverse, some ISGs block pathogens replication, while other ISGs itself are components 
of the IFN pathway, promoting its own signaling. IFN also induces several negative 
regulators that can target PRR, IRFs, or JAK/STAT to dampen the response. 
One renowned group of ISGs is the antiviral genes that have been studied in the 
field for more than 25 years161. ‘Classical ISGs’ in this group include PKR (also known 
as EIF2AK2), MX1, OAS1 and more recently discovered such as APOBEC3G, TRIM5, 
ZAP, ISG15, ADAR, IFITM1/2/3, tetherin (also known as BST2), and viperin (also 
known as RSAD2)162. There is a large scale study done recently, which screened more 
than 380 human ISGs for their ability to inhibit the replication of several important 
human and animal viruses, including hepatitis C virus, yellow fever virus, West Nile 
virus, chikungunya virus, Venezuelan equine encephalitis virus and human 
immunodeficiency virus type-1. They identified broadly acting effectors included IRF1, 
C6orf150 (also known as MB21D1), HPSE, RIG-I (also known as DDX58), MDA5 (also 
known as IFIH1) and IFITM3, whereas more targeted antiviral specificity was observed 
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with DDX60, IFI44L, IFI6, IFITM2, MAP3K14, MOV10, NAMPT (also known as 
PBEF1), OASL, RTP4, TREX1 and UNC84B (also known as SUN2). Clinically, IFN is 
used to treat several viral infections especially it is a key component of HCV treatment, 
one of the mechanism is believed to induce the antiviral genes to directly target virus life 
cycle. 
STAT1 and IRF7 are widely known as an ISG that can reinforce the canonical type I 
IFN signaling which amply the type I IFN production as well as response163-165. Except this 
positive regulation, some ISGs also act as negative regulators for example SOCS family 
members. Most cytokines, if not all, induce SOCS family members, including type I IFN166. 
Growing evidences show SOCS1 and SOCS3 function as negative regulators of JAK-STAT-
mediated signaling and gene activation167,168. For example, Yokato and colleagues revealed 
that type I IFN induced SOCS3 herpes simplex virus-1 (HSV-1) in the host T-cell line 
CCRF-CEM and FL cells is required for efficient replication of the virus. The mechanism is 
still not clearly understood. Studies suggest SOCS1 may bind to the IFN receptors first, and 
then interact with JAKs, whereas the SH2 domain of SOCS3 has been proposed mainly 
binds to gp130-related receptors, through the phosphorylated Tyr757 residue. SOCS3 
may also interact with the receptor first, then with JAKs169,170. 
On the other hand, a mechanism that widely proposed to contribute to the efficacy 
of IFN-β therapy on Relapsing Remitting Multiple sclerosis (RRMS), IL-10 and IL-27 
produced by APCs are two important ISGs and will be intensively introduced herein as 





Fig.6. Subunits of IL-27.  




IL-27 is a heterodimeric cytokine of the IL-6/IL-12 family of type I cytokines172. It is 
composed of the two subunits p28, a p35-related molecule, and Epstein-Barr virus-
induced gene 3 (EBI-3), a p40-related molecule173. EBI-3 is also known to 
heterodimerize with p35 to form another cytokine called IL-35174. IL-27 is mainly 
produced by classical antigen-presenting cells (APCs), including macrophages and DCs, 
when stimulated with PAMPs and TLR agonists174. In monocytes/macrophages and DCs, 
EBI-3 is induced in response to LPS stimulation, CD40 ligation, or other inflammatory 
cytokine stimuli, such as IFN-β172. The same inflammatory stimuli also induce the 
expression of p28, hence promoting the secretion of the heterodimeric cytokine172. TLR 
ligand-induced EBI-3 expression in DCs was found to be dependent on MyD88 and NF‑
34 
 
κB p50/p65175, while p28 expression in macrophages and DCs was found to be dependent 
on both MyD88 and TRIF signaling, and mediated by NF‑κB c-Rel, IRF1, IRF3 and 
IRF8176-178.  
IL-27 signals through its cognate receptor complex IL-27R, which consists of a 
unique subunit IL-27Rα (also known as WSX-1 or T cell cytokine receptor (TCCR)) and 
a common subunit gp130 (shared with the IL-6R receptor complex), which is also the 
signal transducing subunit173. While the expression of IL-27R on T cells is well known 
and the effects of IL-27 on T cells are well studied, the receptor complex is also 
expressed on innate immune cells, including monocytes/macrophages, DCs, Langerhan’s 
cells and NK cells179. Upon IL-27 binding to its cognate receptor, JAK-STAT signaling is 
initiated, and STAT1 and STAT3 transcription factors are activated173. It has been 
reported that IL-27-mediated IL-10 production in T cells, and the associated immuno-
suppressive functions of IL-27, are dependent on STAT1 and STAT3 activation180. IL-27 
is a pleiotropic cytokine with both inflammatory and immuno-suppressive properties: the 
former through the initiation of Th1 commitment and Th1 responses to infections, as well 
as through the inhibition of inducible Treg (iTreg) conversion; the latter through the 
inhibition of Th17 development and IL-17 production, as well as through the induction of 
IL-10 production by activated T cells, as mentioned above174. Apart from T cells, IL-27 
also suppresses the function of macrophages and DCs by inhibiting cytokine production, 
such as TNF-α and IL-12 production, by activated macrophages181. Recently, IL-27 has 
been implicated in LPS-induced IL-10 expression in macrophages, via the sequential 
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induction of IFN-β followed by IL-27182. In this way, IL-27 acts as a general immuno-
suppressant in both the innate and adaptive immune responses. 
1.7.2 Interleukin-10 
IL-10 is a type II cytokine with one of the most potent anti-inflammatory activities, first 
discovered as a “cytokine synthesis inhibitory factor” (CSIF) produced by Th2 cells, that 
acts directly on T cells to inhibit Th1-cell effector functions and cytokine production (e.g. 
the Th1-associated cytokines IL-2, IFN-γ and TNF-α)183,184. The immuno-suppressive 
effects of IL-10 are important to restrain inflammation during the resolution phase of 
infections: dysregulation of IL-10 levels is associated with either an increased 
susceptibility to infections on the one hand, or an increased susceptibility to auto-immune 
diseases on the other hand185. IL-10 is expressed by cells of the adaptive immune system, 
such as various T cell subsets and B cells, as well as by cells of the innate immune 
system, including macrophages, DCs, NK cells and neutrophils186.  
Myeloid cells constitute a major source of IL-10: macrophages and myeloid DCs, 
but not plasmacytoid DCs, produce IL-10 upon TLR stimulation during infection187. 
Optimal levels of LPS-induced IL-10 production in macrophages have been shown to 
require both MyD88- and TRIF-dependent signaling, as well as type I IFN production 
and signaling186,188. As mentioned above, IL-27 can induce IL-10 in macrophages and T 
cells in a STAT1- and STAT3-dependent manner180,182,189. IL-10 signals through its 
cognate receptor complex, which comprises two chains each of IL-10 receptor 1 (IL-
10R1) and IL-10R2, and propagates signals through JAK1 and Tyk2 and STAT3 to 
culminate in the transcriptional activation of STAT3-responsive genes, such as SOCS1 
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and SOCS3, that execute the anti-inflammatory response183,184,190. IL-10 mainly acts on 
APCs, such as macrophages and DCs, in which the expression of the IL-10R receptor 
complex is highest, to regulate their pro-inflammatory activities. It has been described to 
inhibit the TLR-induced expression of pro-inflammatory cytokines TNF-α, IL-1 and IL-
6; Th1-inducing cytokines IL-12 and IL-18; inflammatory chemokines CCL2-5, CXCL8 
and CXCL10; and cell surface molecules such as MHC class II and CD80/86 co-
stimulatory molecules, and therefore inhibits the subsequent activation of Th1-type 
responses183,185,186,190. Through multiple mechanisms, IL-10 plays an important role in the 
















1.8 Rationale of the study 
 
We and others have previously reported a more rapid and higher level of IFN-β induction 
in monocytes/macrophages following pathogenic stimulation, in contrast to non-myeloid 
cells153. In DCs, IFN-β induction in response to viral infection exhibits biphasic kinetics 
with two distinct peaks191. Extensive studies have demonstrated that the “second phase” 
of IFN-β transcription, which contributes to the IFN-β positive feedback loop, in the 
context of viral infection is dependent on IRF7 in fibroblasts115, and IRF8 in DCs191. 
Fibroblasts deficient in IFN-β, IFNAR or IRF7 exhibit defective IFN-β production192, 
while the second peak of IFN-β induction is absent in DCs lacking IFNAR or IRF8191,193. 
Through this IFN-β autocrine/paracrine positive feedback loop, an optimal level of IFN-β 
induction in DCs is shown to be functionally important for the expression of downstream 
cytokine genes, such as interleukin-(IL-)12p70193 and tumor necrosis factor-(TNF-)α194, 
as well as for the expression of co-stimulatory molecules, such as CD40 and CD86194,195, 
which play a role in bridging innate and adaptive immunity. For example, through IL-
12p70 secretion, IFN-β enhances IFN-γ production by natural killer (NK) cells and T 
cells, and thereby promotes Th1-cell development and Th1 responses196. On the other 
hand, there is circumstantial evidence suggesting that the IFN-β autocrine/paracrine 
positive feedback loop also exists in LPS-stimulated macrophages. For instance, 
neutralizing antibodies against IFN-β (but not IFN-α) reduced LPS-induced STAT1 
tyrosine phosphorylation in primary murine macrophages197, while cytokine gene 
expression of e.g. IL-12p40, inducible nitric oxide synthase (iNOS) and IP-10/CXCL10, 
as well as cytokine secretion of e.g. IL-12p70 and IP-10/CXCL10, were suppressed in 
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IFN-β -/- murine peritoneal macrophages198. However, IFN-β -/- mice/cells do not allow us 
to conclude whether the induction IFN-β itself is directly dependent on type I IFN 
signaling through the IFNAR. Moreover, since biphasic kinetics was not observed in 
LPS-stimulated macrophages (we observed only a single peak at 1-2 h after LPS 
stimulation of primary murine macrophages), the molecular mechanisms (i.e. the 
mediators involved) and the functional significance of the IFN-β autocrine/paracrine 
positive feedback loop in LPS-stimulated macrophages are less clear. 
Apart from promoting the production of pro-inflammatory cytokines and 
chemokines, such as IL-12p70, iNOS and IP-10/CXCL0, the anti-inflammatory actions 
of IFN-β are increasingly recognized. For instance, the involvement of the type I IFN 
autocrine/paracrine loop has been reported in the induction of suppressor of cytokine 
signaling-(SOCS-)-1 and SOCS-2 by LPS-stimulated macrophages and DCs199,200. The 
members of the SOCS family of proteins are generally regarded as negative regulators of 
JAK-STAT signaling, e.g. by blocking STAT1 activation. IFN-β-induced SOCS1 reduces 
cell surface expression of MHC class II and CD40 co-stimulatory molecule, and thereby 
inhibits antigen presentation and T cell activation201. One of the most compelling 
examples of the anti-inflammatory effects of IFN-β is its clinical use in the treatment of 
relapsing-remitting multiple sclerosis (MS)201. The mechanisms of action of IFN-β 
therapy for relapsing-remitting MS are under continuing investigation, but have been 
suggested to include suppression of T cell activation, inhibition of pro-inflammatory 
cytokine production (e.g. IL-12 and TNF-α), and stimulation of anti-inflammatory 
cytokine production (e.g. IL-4 and IL-10) 201. It has been proposed that IFN-β decreases 
T cell activation by increasing the prevalence and inhibitory capacities of naturally-
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occurring regulatory T cells (nTregs)202,203, and by increasing the production of IL-27 and 
IL-10 by DCs and CD4+ T cells, to constrain Th17-mediated autoimmune 
inflammation204,205. The negative regulation of Th17 development and IL-17 production 
have been attributed to TRIF-dependent type I IFN production and signaling via IFN-β-
mediated IL-27 production in macrophages and DCs206. Recently, the elucidation of the 
signaling pathway leading to LPS-induced IL-10 expression in macrophages, involving 
the sequential induction of IFN-β production and signaling followed by IL-27 production 
and signaling, further sheds light on the immuno-modulatory functions of IFN-β182,188. 
Here, in this study, we ask whether an IFN-β autocrine/paracrine positive 
feedback loop exists in LPS-stimulated murine macrophages, and investigated the 
molecular mechanisms and functional significance of this amplification loop. Using 
IFNAR1-deficient bone marrow-derived macrophages (BMMs), we clearly demonstrated 
that an IFN-β autocrine/paracrine loop is operational in LPS-stimulated BMMs. 
Consistent with other published reports, IFN-β production and signaling is required for 
downstream IL-27 induction. Surprisingly, we found that IFN-β induction is impaired in 
BMMs lacking IL-27p28, suggesting that IL-27 production engages IFN-β in a positive 
feedback loop to amplify IFN-β expression. IL-27 production and signaling is important 
for the induction of optimal levels of IFN-β in response to both LPS stimulation and IFN-
β stimulation. Interrogation of signal transduction mediators revealed that STAT1 
tyrosine phosphorylation is significantly attenuated but not completely abolished in 
BMMs lacking IL-27p28 at 1h after LPS stimulation. Functional consequences of 
reduced IFN-β expression in the absence of IL-27 production and signaling are reflected 
in decreased levels of induction of several ISGs to varying extents. In line with previous 
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reports that IL-27 can induce IL-10 expression, IL-10 production is impaired in BMMs 
lacking IL-27p28. However, importantly, we discovered that this defect in IL-10 
expression in the absence of IL-27 production and signaling can be restored by the 
addition of exogenous IFN-β, thus contesting the current proposed model that a 
sequential induction of IFN-β followed by IL-27 leads to IL-10 production. Addition of 
exogenous IFN-β also restores IL-10 mediated suppression of the pro-inflammatory 
cytokines TNF-α, IL-6 and IL-12. Therefore, we propose that the IFN-β amplification 
loop in LPS-stimulated BMMs is mediated by IL-27 production and signaling, and that 
the high levels of IFN-β production downstream of IL-27 is critical for the induction of 
















Chapter 2: Materials and Methods 
 
Mice 
All mice were derived from C57BL/6 genetic background. TRIF−/−, IFNAR1−/− and 
IRF1−/− mice were from The Jackson Laboratory. IFNAR1−/− were backcrossed to 
C57BL/6 for at least 5 generations. IRF3−/− and IRF7−/− mice were obtained from Riken, 
Japan. STAT1−/− were purchased from Taconic and then backcrossed to C57BL/6 for at 
least 5 generations. MyD88−/− mice were from Dr. Shizuo Akira (Osaka University, 
Japan). IL-27p28−/− and WSX-1−/− bone marrow were obtained from Dr. Hiroki Yoshida 
(Saga University, Japan), the latter from WSX-1−/− mice provided by Amgen, Inc. 
(Thousand Oaks, USA). STAT2m/m (P117) and MxCre-STAT3f/f bone marrow were 
obtained from Dr. Chien-Kuo Lee (National Taiwan University, Taiwan). All mice were 
maintained and bred under specific pathogen-free conditions. All experiments were 




LPS (L4516, L2630) was from Sigma-Aldrich. Murine IFN-α and IFN-β were from 
Millipore, and murine IL-10 was from R&D Systems. Antibody reagents for Western 
immunoblotting included anti-IRF7 (Invitrogen), anti-IRF3 and anti-α-tubulin (Santa 
Cruz Biotechnology), anti-STAT1 and anti-phospho-STAT1 (Tyr 701) (BD 




 Preparation of BMDMs and BMDCs 
BMDMs were generated by flushing bone marrow cells from the femurs and tibias of 
mice. BM cells were cultured for 7d in DMEM containing 20% FBS, penicillin 
(100U/ml), streptomycin (100μg/ml), and 30% conditioned medium (CM) from L929 
cells overexpressing M-CSF. BMDMs were then stimulated or not with 100ng/ml LPS in 
the presence or absence of 500U/ml IFN-α, 250U/ml IFN-β or 10ng/ml IL-10 for the 
indicated times. For BMDCs, BM cells were cultured for 6d in RPMI supplemented with 
10% FBS, penicillin (100U/ml), streptomycin (100μg/ml), and 20ng/ml recombinant 
mouse GM-CSF (Prospec). GM-CSF was replenished every 2d and the non-adherent 
cells were harvested on d5 and rested overnight before use in experiments. 
 
Cell Culture 
Cell lines HEK293 were obtained from the American Type Culture Collection and 
cultured at 37°C, 5% CO2 in DMEM medium supplemented with 10% heat-inactivated 
fetal bovine serum (Invitrogen, Carlsbad, USA) and 1000 U/mL penicillin/streptomycin.  
 
Western immunoblotting 
Whole-cell lysates were prepared in radio-immunoprecipitation assay (RIPA) buffer at 
4°C for 1h. Lysates were clarified by centrifugation at 12,000g for 10min and the protein 
concentration was determined using a Protein Assay Dye Reagent Concentrate (Bio-
Rad). Protein samples were denatured by addition of reducing SDS loading buffer and 
boiling at 95oC. Equal amounts of sample lysates were separated by 9% SDS-PAGE, 
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transferred onto PVDF membranes, blocked in 5% milk or BSA, and probed with 
specific antibodies. 
 
Enzyme-linked immunosorbent assay (ELISA) and Luminex multiplex assay 
Culture supernatants were assayed using ELISA kits for the detection of murine IL-27 
(eBioscience) and IFN-β (PBL InterferonSource) according to the manufacturer’s 
instructions. Bio-Plex Pro™ magnetic colorbead-based multiplex assays (Bio-Rad 
Laboratories, Inc.) were used to measure all other cytokines. Fluorescence intensity was 
acquired and analyzed using the Bio-Plex™ 200 System (V6.0; Bio-Rad Laboratories, 
Inc.). 
 
Real-time quantitative PCR (Q-PCR) 
Total RNA was extracted using Trizol (Invitrogen) and purified using RNeasy mini-kits 
(Qiagen). For cDNA synthesis, 1μg total RNA was used with the SuperScript II kit 
(Invitrogen) according to the manufacturer’s instructions. Endogenous mRNA levels 
were measured by real-time PCR using SYBR Green (Kapa Biosystems) detection with 
the ABI Prism 7900HT machine (Applied Biosystems). Real-time PCR primers are 
shown in Table 1. Each primer was assessed using human genome Blast searches to 
exclude cross-reactivity, and all primer pairs generated a single product of the expected 






Chromatin immunoprecipitation (ChIP) 
BMDMs were cross-linked with 1% formaldehyde at room temperature for 8min and 
quenched using 125mM glycine. Crosslinked chromatin and associated proteins were 
isolated and sonicated to produce chromatin fragments of mean 500bp each. Chromatin 
fragments were immunoprecipitated using bead-bound IgG and anti-STAT1 antibodies 
(Santa Cruz sc-345) or anti-Pu.1 antibodies (sc-22805). The method for ChIP has been 
described in detail elsewhere153. Real-time PCR analyses were performed using the ABI 
Prism 7900HT machine (Applied Biosystems). ChIP data were normalized to and 
expressed as percent of input. Real-time PCR primers used to quantitate ChIP-enriched 
DNA are shown in Table 2. 
 
LPS challenge septic shock 
Mice were injected i.p. with LPS in sterile PBS (30μg/g body weight) and serum was 
obtained from retro-orbital bleeding after 3h. Mice were injected i.p. with LPS in sterile 
PBS (30μg/g body weight) and survival was monitored for 72h thereafter. Six- to 8-
week-old gender- and age-matched mice were used in all experiments. 
 
Luciferase reporter assays  
HEK293 cells were transfected with lipofectamine (Life Technologies, NY, USA) and 
luciferase activity was detected using a luciferase assay kit (Promega, Wisconsin, USA). 
Cells (3x104) were transfected with the reporter (100ng plasmids), effectors (50ng 





Retroviral constructs pMSCV-PU.1 was gift from Dr. Thomas Graft (Institució Catalana 
de Recerca i Estudis Avançats, Barcelona, Spain). Retrovirus was generated by 
transfection of the constructs in retrovirus packaging cell line named Platinum-E (Plat-E) 
using Lipofectamine 2000 (Life Technologies). Virus supernatant was harvested 48h 
after transfection. For transduction, BMDMs were treated with 5μg/ml polybrene and 
viral supernatant for 24h on day2 and day5 respectively.  
 
Statistics 
Statistical analyses were performed using GraphPad Prism (GraphPad Software, Inc.). 
Ordinary one-way ANOVA or Ratio paired t test, as indicated in figure legends, was used 
to analyze differences in mean values between groups. All results are expressed as mean 
values ± standard deviation (SD) or mean values ± standard error of the mean (SEM), as 





Table 1. Real-time PCR primers. 
Primers Sequence (5’ to 3’) 
mIFNb1 Forward ACACCAGCCTGGCTTCCATCATGAACAACA 
mIFNb1 Reverse TTCAAATGCAGTAGATTCACTACCAGTCCC 
mIL-27 Forward CTCTGCTTCCTCGCTACCAC 
mIL-27 Reverse GGGGCAGCTTCTTTTCTTCT 
mIL-10 Forward AAGGACCAGCTGGACAACAT 
mIL-10 Reverse TTTTCACAGGGGAGAAATCG 
mCCL-5 Forward CCCTCACCATCATCCTCACT 
mCCL-5 Reverse CCACTTCTTCTCTGGGTTGG 
mCXCL-10 Forward AAGTGCTGCCGTCATTTTCT 
mCXCL-10 Reverse TTTTTGGCTAAACGCTTTCAT 
mCXCL-11 Forward AACAGGAAGGTCACAGCCATAG 
mCXCL-11 Reverse TTTGTCGTTTATGAGCCTTCATAGT 
mIRF-7 Forward GCATTTCGGTCGTAGGGATCTGGATGAAGA 




Table 2. Real-time PCR primers used to quantitate ChIP-enriched DNA. 
Primers Sequence (5’ to 3’) 
mIRF-7 Enhancer Forward GCTTCTTGACCCAGCTGGAACA 
mIRF-7 Enhancer Reverse ACAGTCAAGGGTTGTGTCCATCCT 
mIFN-β Promoter Forward  TCCAGCAATTGGTGAAACTGTACAAGATTT 







Current opinion on the “canonical type I IFN gene induction model” stimulated by virus 
in most cell types, such as fibroblasts and conventional dendritic cells (cDCs) is a 
positive-feedback loop involved both IRF3 and IRF7, which are essential for the 
amplification of IFN-α/β transcription. Once the viral pathogen-associated molecular 
patterns (PAMPs) are detected by cytosolic pattern recognition receptors (PRRs), 
phosphorylation of IRF3 and IRF7, forming their homo- or heterodimerization and 
nuclear translocation, produces the first phase early secretion of small amounts of type I 
IFN. Via an autocrine/paracrine manner, this early phase type I IFN in turn bind and 
activate the type I IFN receptor, resulting in IRF7 induction by the IFNAR-Tyk2/Jak1-
ISGF3 pathway. The newly synthesized IRF7 reinforce the IRF7 in the first phase then 
amplify type I IFN by producing the second phase expression of large amounts of IFN-β 
and many of the IFN-α proteins, as well as the IFN-stimulated genes (ISGs), including 
many antiviral genes119,121. 
Macrophage production of type I IFNs following endotoxin exposure is a key 
component of host homeostasis and critical regulator of inflammatory responses to Gram-
negative bacterial infection. However, apart from the current understanding that LPS-
induced IFN-β gene expression is mediated by the MyD88-independent, TRIF-dependent 
activation of IRF3119,121,146,207, there is no conclusive information on the existence of a 
positive feedback regulation of the IFN-β gene itself by autocrine/paracrine type I IFN 
signaling. In macrophages, LPS stimulation of TLR4 induces the expression of primary 
response genes, including the immediate early gene IFN-β, and the secondary response 
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genes, such as CCL5 (also known as RANTES), CXCL10 (also known as IP-10), NOS2 
(also known as iNOS), IRF1 and IRF7, the optimal expression of a subset of which are 
dependent on the indirect activation of STAT1 by intermediate production of IFN-β and 
autocrine/paracrine type I IFN signaling146,197,198,208, suggesting that the type I IFN 
receptor is operating in the system but whether it serve a positive feedback mechanism 
for type I IFN is still an open question in the field. On the one hand, lipid A-induced IFN-
β mRNA levels were not considerably changed in IFNAR-knockout bone marrow-
derived macrophages compared with wild-type at 1hr and 4hrs after treatment209. On the 
other hand, both basal and LPS-induced IFN-β mRNA levels were substantially reduced 
in Tyk2-null peritoneal macrophages compared with wild-type, suggesting that Tyk2 
downstream of IFNAR is required for normal IFN-β induction210. Having said that, the 
signaling adaptor molecule Tyk2 is not specific to type I IFN signaling: in addition to 
IFNAR, it also transduces signals downstream of multiple cytokine receptors, including 
IFN-γ, IL-6, IL-10 and IL-12 receptors211,212. 
Therefore, we first sought to obtain definitive evidence on the involvement of an 
IFN-β autocrine/paracrine feedback in the induction of high IFN-β production observed 
upon LPS stimulation of macrophages. That is the initiative of this study when we first 
started.  
 
3.2 IL-27p28 and type I interferon receptor signaling support amplification of IFN-β 
responses in LPS-stimulated macrophages 
To better elucidate the regulation of LPS induced IFN-β, we stimulated primary murine 
BMDMs with LPS and profiled the kinetics of IFN-β induction. LPS elicited rapid yet 
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transient IFN-β expression (Fig. 7a, 7b), whereas IFN-α was not detected as previous 
studies reported138,213. LPS-stimulated IFN-β transcription and protein secretion peaked at 
2h, followed by a rapid decline in IFN-β mRNA levels (6h)197,198,210, and cytokine output 
(24h) (Fig. 7a, b). To further define the possible autocrine/paracrine mechanism in this 
response, we checked  BMDMs from IFNAR1-knockout mice and found that the mutant 
displayed negligible IFN-β mRNA expression and protein secretion in response to LPS 
(Fig. 8a, b), indicating that type I IFN signaling promotes maximal IFN-β production in 
LPS-stimulated macrophages within just 2h of endotoxin exposure. In contrast, autocrine 
amplification of type I IFN responses in virus-challenged fibroblasts and dendritic cells 
(DCs) occurs only at late time points (>6h) after infection106,191. Type I IFN signaling 
upon IFNAR engagement was previously shown to be mediated by the heterotrimeric 
complex of STAT1-STAT2-IRF9 (ISGF3) or the STAT1-STAT1 homodimer (GAF)137. 
Accordingly, LPS-stimulated IFN-β expression was almost entirely abrogated in STAT1-
deficient BMDMs (Fig. 8c, d) and STAT2-mutant BMDMs (Fig. 8e, f), supporting the 
concept that autocrine/paracrine type I IFN signaling through ISGF3 enhances IFN-β 
responses in LPS-stimulated macrophages.  Although the autocrine/paracrine positive 
feedback amplification mechanism similar to virus-stimulated DCs and fibroblasts is 
observed in LPS-challenged macrophages, the biphasic kinetics was not observed in LPS-
stimulated macrophages (Fig. 7a-c), suggesting a similar but different mechanism. 
Moreover, LPS stimulation induced macrophage accumulation of IFN-β mRNA within 
just 2h of endotoxin exposure, while addition of exogenous IFN-β cytokine in the 
absence of LPS failed to substantially increase IFN-β transcription (Fig. 7c), indicating 
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that both type I IFN signaling and TLR4 activation together are required to amplify IFN-
β responses in macrophages. 
 These data demonstrated a key function for IFN-β signaling in the amplification 
of IFN-β expression in LPS-stimulated macrophages. Our results further suggested that 
maximal IFN-β synthesis depends on an IFNAR-mediated positive feedback loop driven 
by an ISGF3 target molecule expressed in macrophages. 
IL-27p28 is a key LPS-inducible gene in myeloid antigen presenting cells that 
requires autocrine/paracrine type I IFN signals and ISGF3 activation to promote optimal 
cytokine production176,177,182,214. We therefore sought to determine whether IL-27p28 
influenced IFN-β responses in endotoxin-challenged macrophages. We first performed a 
detailed kinetic analysis of IFN-β and IL-27p28 expression in LPS-stimulated 
macrophages, and observed that peak IFN-β mRNA expression and near-maximal protein 
expression coincided with induction of IL-27p28 transcription and the first detection of 
IL-27 cytokine in the culture supernatants (Fig. 9a, 8b, 11a), suggesting the possible 
crosstalk in between two cytokines/genes. We further discovered that LPS-stimulated 
expression of IL-27p28 was reduced in IFNAR1-knockout BMDMs compared with wild-
type BMDMs182 (Fig. 11b, c). Indeed, expression of IL-27p28 mRNA and protein were 
similarly diminished in STAT1-deficient BMDMs and STAT2-mutant BMDMs after 
LPS challenge (Fig. 11d-g), suggesting that IL-27p28 could be a critical intermediate-
response gene induced by type I IFN/ISGF3 signaling in LPS-stimulated macrophages. 
Indeed, we observed that IFN-β expression was enhanced by LPS stimulation in BMDMs 
from IL-27p28-knockout mice (Fig. 9b, 9c). These results indicated that IL-27p28 
production and signaling are required for the amplification of IFN-β responses in LPS-
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stimulated macrophages. This is the very first report that demonstrates cytokines (IL-
27p28) might work upstream of LPS induced IFN-β and are involved in its regulation. 
Accordingly, gene expression analysis further supported that LPS-inducible type I IFN-
dependent chemokine genes Ccl5, Cxcl10 and Cxcl11138,146,198 were down-regulated in 
IL-27p28 knockout BMDMs (Fig. 9d). Together, these data that LPS induction of a 
subset of type I IFN-response genes depends on the high levels of IFN-β production 
achieved in IL-27p28-sufficient macrophages, highlighting the physiological significance 
of this optimal level of IFN-β. 
On the other hand, we found that IFN-β responses to LPS are completely 
abolished in TRIF-deficient BMDMs (Fig. 10a, 10b, 12b), whereas IFN-β synthesis is not 
entirely ablated in IL-27p28-knockout BMDMs (Fig. 9b, 9c, 12a). Consistent with these 
data, immunoblot analyses revealed that total STAT1 expression and LPS-induced 
STAT1 phosphorylation is attenuated in IL-27p28-knockout BMDMs (Fig. 10c). 
Accordingly, co-treatment with recombinant IFN-β and LPS rescued STAT1 
phosphorylation in IL-27p28-BMDMs, suggesting that IL-27p28-mediated IFN-β 
production and autocrine/paracrine type I IFN signaling are required to support full 
STAT1 activation in BMDMs (Fig. 12c). In contrast, TRIF-deficient BMDMs, which 
entirely lack the ability to produce IFN-β, displayed unaltered levels of total STAT1 
expression and negligible STAT1 phosphorylation after LPS exposure (Fig. 10d), 
reflecting the greater depletion of IFN-β expression in TRIF-deficient BMDMs (Fig. 10a, 
10b), compared to the expression in IL-27p28-knockout BMDMs (Fig. 9b, 9c). 
Taken together, these data indicate that IL-27p28 and type I IFN signaling are 
important to support robust IFN-β production, which is subsequently required for optimal 
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STAT1 activation, and efficient transcriptional induction of interferon-inducible genes, 




 Fig.7. Macrophage IFN-β responses are rapidly and transiently induced by LPS exposure 
but not by exogenous IFN-β cytokine.  
Analysis of IFN-β gene and protein expression by real-time PCR (a,c) and ELISA(b) 
analysis of cell culture supernatants in wild-type BMDMs stimulated or not with 
100ng/ml LPS or 250U/ml recombinant murine IFN-β for the indicated times. Ifnb1 
expression was normalized to Gapdh and is expressed relative to the levels observed in 
un-stimulated wild-type control cells. Data are presented as the mean ± SD of duplicate 
determinations from one independent experiment of at least three conducted. WT, wild-
type. N.D. not detected. 
 
 
Fig.8. Type I IFN autocrine/paracrine signaling via ISGF3 amplifies IFN-β gene and 
protein expression in endotoxin-challenged macrophages.  
Analysis of IFN-β gene and protein expression by real-time PCR and ELISA analysis of 
cell culture supernatants in BMDMs from IFNAR1 knockout mice (a, b), STAT1 
knockout mice (c, d), and STAT2 mutant mice (e, f), together with their respective wild-
type control littermates. BMDMs were stimulated or not with 100ng/ml LPS for the 
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indicated times. Ifnb1 expression was normalized to Gapdh and is expressed relative to 
the levels observed in un-stimulated wild-type control cells. Data are presented as the 
mean ± SD of duplicate determinations from one independent experiment of three 
conducted. WT, wild-type. KO, knockout. N.D. not detected. 
 
 
Fig.9. IL-27p28 production is required for amplification of macrophage IFN-β responses 
to LPS.  
(a) Real-time PCR analysis of the kinetics of Ifnb1 and Il27 gene expression in wild-type 
BMDMs following stimulation with 100ng/ml LPS. Data were normalized to Gapdh and 
are expressed relative to the levels observed in un-stimulated cells. Analysis of IFN-β 
gene and protein expression by real-time PCR and ELISA analysis of cell culture 
supernatants in BMDMs from IL-27p28 knockout mice (b, c) with it respective wild-type 
control littermates. BMDMs were stimulated or not with 100ng/ml LPS for the indicated 
times. (d) Real-time PCR analysis of Ccl5, Cxcl10 and Cxcl11 gene expression in 
BMDMs from IL-27p28 knockout mice, together with their respective wild-type control 
littermates. Gene expression data were normalized to Gapdh and are expressed relative to 
the levels observed in un-stimulated wild-type control cells. Data shown in (a-d) are 
presented as the mean ± SD of duplicate determinations from one independent 






Fig.10. Trif and IL-27p28 are required for amplification of macrophage IFN-β responses 
to LPS.  
(a, b) Analysis of IFN-β gene and protein expression by real-time PCR and ELISA 
analysis of cell culture supernatants in BMDMs from TRIF knockout mice, together with 
their respective wild-type control littermates. (c, d) Western immunoblot analysis of 
phospho-STAT1 and total STAT1 protein expression in whole cell lysates of BMDMs 
from IL-27p28 knockout mice (c) and TRIF knockout mice (d), together with their 
respective wild-type control littermates. BMDMs were stimulated or not with 100ng/ml 
LPS for the indicated times. Gene expression data were normalized to Gapdh and are 
expressed relative to the levels observed in un-stimulated wild-type control cells. Data 
shown in (a, b) are presented as the mean ± SD of duplicate determinations from one 
independent experiment of at least 3 experiments. Data shown in (c, d) are representative 







Fig.11. Induction of IL-27p28 requires type I IFN signaling through the ISGF3 complex.  
(a) ELISA analysis of IL-27 protein expression in cell culture supernatants of BMDMs 
stimulated or not with 100ng/ml LPS for the indicated times. Analysis of IL-27 gene and 
protein expression by real-time PCR and ELISA analysis of BMDMs from IFNAR1 
knockout mice (b, c), STAT1 knockout mice (d, e), and STAT2 mutant mice (f, g), 
together with their respective wild-type littermates. BMDMs were stimulated or not with 
100ng/ml LPS for the indicated times. Gene expression data were normalized to Gapdh 
and are expressed relative to the levels observed in un-stimulated wild-type control cells. 
Data shown in (a-g) are presented as the mean ± SD of duplicate determinations from one 






Fig.12. STAT1 activation upon LPS stimulation requires full level of type I IFN in 
BMDMs.  
(a, b) Replotted data from Fig. 9b, 10a but are presented on a scale that illustrates the 
residual induction of IFN-β transcription in IL-27p28 knockout mice (a), and TRIF 
knockout mice (b). BMDMs were stimulated or not with 100ng/ml LPS for the indicated 
times. (c) Assessment of phospho-STAT1 and total STAT1 protein expression Western 
immunoblot analysis of whole cell lysates of BMDMs from IL-27p28 knockout mice 
together with the respective wild-type control littermates. BMDMs were treated or not 
with 100ng/ml LPS either alone or in combination with 250U/ml recombinant murine 
IFN-β for 1-3h. Gene expression data were normalized to Gapdh and are expressed 
relative to the levels observed in un-stimulated wild-type control cells. Data shown in (a, 
b) are presented as the mean ± SD of duplicate determinations from one independent 




3.3 IRF7 and IRF3 act in concert to induce maximal IFN-β expression in LPS-
stimulated macrophages 
Transcription factor Signal transducer and activator of transcription 3 (STAT3) is 
reportedly activated downstream of IL-27R signaling to promote T cell production of IL-
10 and to support monocyte expression of pro-inflammatory mediators180,215. However, 
our data showed that IFN-β expression in response to LPS was instead increased in 
STAT3-knockout BMDMs compared with wild-type BMDMs216 (Fig. 13a, 13b). 
Similarly, another transcription factor IRF1 is known to be essential for IFN-β induction 
in CpG-stimulated myeloid dendritic cells (mDCs)118,121, and in TNF-stimulated 
monocytes and macrophages217, but we observed that IFN-β expression was largely 
unchanged in IRF1-deficient BMDMs compared with wild-type BMDMs after LPS 
stimulation (Fig. 15a, 15b). Therefore, we proceeded to assess the other transcription 
factors implicated in TLR-mediated type I IFN induction. 
Induction of IFN-β expression is primarily controlled by the interferon regulatory 
factor (IRF) proteins IRF3 and IRF7 in various cells under exposure of different 
stimulus115,119,121,146,218. IRF7 is widely regarded as the ‘master regulator’ of type I IFN 
responses in viral infection115,119,121, but IRF7 is not required to mediate IFN-β responses 
in LPS-stimulated DCs115. Consequently, IFN-β induction following TLR4 ligation is 
thought to be mainly transcriptionally mediated by IRF3207. However, we observed that 
LPS-induced IFN-β expression was equally impaired in both IRF7-null (Fig. 13c, 13d) 
and IRF3-null (Fig. 13e, 13f) BMDMs compared with wild-type cells. Consistent with 
these data, LPS-stimulated STAT1 phosphorylation and type I IFN-dependent chemokine 
gene expression were also comparably decreased in both IRF7- and IRF3-null BMDMs 
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relative to wild-type cells (Fig. 14a-d). It is also notable that IFN-β expression is not 
entirely ablated in IRF7- or IRF3-null BMDMs, since residual IFN-β transcription and 
small quantities of IFN-β cytokine were detected in the culture supernatants following 
LPS stimulation (Fig. 13c-f; Fig. 15c, 15d). These data were in agreement with our earlier 
observation that LPS stimulation can elicit limited production of IFN-β in IL-27p28-
knockout BMDMs, whereas IFN-β expression is totally abolished in TRIF-deficient 
BMDMs (Fig. 10a, 10b). Accordingly, LPS-stimulated phosphorylation of STAT1 can be 
detected at low levels in IRF7- and IRF3-null BMDMs (Fig. 12a, 12b), and in IL-27p28-
BMDMs (Fig. 10c), but not in TRIF-deficient BMDMs (Fig. 10d). When taken together 
with our finding that IRF3 expression is essentially normal in IRF7-null macrophages, 
and that IRF7 levels are largely unaltered in IRF3-null macrophages (Fig. 15e, 15f), these 
data suggested that IRF3 and IRF7 are not mutually affected by each other, whereas they 
both are required in combination to achieve maximal IFN-β production in endotoxin-
challenged macrophages. Whereas in DCs, regulation of LPS induced IFN-β depends on 
IRF3 but not IRF7. Our findings are not only in line with current dogma but also offer 
new insights to the long sought question about the role of IRF7 in macrophages upon 
LPS challenge.  
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 Fig.13. Maximal IFN-β expression in endotoxin-challenged macrophages depends on 
IRF7 and IRF3 but not STAT3.  
Analysis of IFN-β gene and protein expression by real-time PCR and ELISA analysis of 
cell culture supernatants in BMDMs from STAT3 knockout mice (a, b), IRF7 knockout 
mice (c, d), and IRF3 knockout mice (e, f), together with their respective wild-type 
control littermates. BMDMs were stimulated or not with 100ng/ml LPS for the indicated 
times. Gene expression data were normalized to Gapdh and are expressed relative to the 
levels observed in un-stimulated wild-type control cells. Data shown in (a-f) are 
presented as the mean ± SD of duplicate determinations from one independent 





 Fig.14. IFN-β downstream responses depends on IRF7 and IRF3 in BMDMs.  
(a, b) Western immunoblot analysis of phospho-STAT1 and total STAT1 protein 
expression in whole cell lysates of BMDMs from IRF7 knockout mice (a), and IRF3 
knockout mice (b), together with their respective wild-type control littermates. BMDMs 
were stimulated or not with 100ng/ml LPS for the indicated times. (c, d) Real-time PCR 
analysis of Ccl5, Cxcl10 and Cxcl11 gene expression in BMDMs from IRF7 knockout 
mice (c), and IRF3 knockout mice (d), together with their respective wild-type control 
littermates. BMDMs were stimulated or not with 100ng/ml LPS for 2h (Cxcl10) or 6h 
(Ccl5 and Cxcl11). Gene expression data were normalized to Gapdh and are expressed 
relative to the levels observed in un-stimulated wild-type control cells. Data shown in (c, 
d) are presented as the mean ± SD of duplicate determinations from one independent 




 Fig. 15. Maximal IFN-β expression in endotoxin-challenged macrophages depends on 
IRF7 and IRF3 but not IRF1.  
Analysis of IFN-β gene and protein expression by real-time PCR and ELISA analysis of 
cell culture supernatants in BMDMs from IRF1 knockout mice compared with wild-type 
control littermates (a, b). BMDMs were stimulated or not with 100ng/ml LPS for the 
indicated times. Panels (c, d) Reproduced data from Fig. 3c, e but are presented on a scale 
that illustrates the residual induction of IFN-β transcription in IRF7 knockout mice (c), 
and IRF3 knockout mice (d). BMDMs were stimulated or not with 100ng/ml LPS for the 
indicated times. (e, f) Western immunoblot analysis of IRF3 protein expression in whole 
cell lysates of BMDMs from IRF7 knockout mice (e), and of IRF7 protein expression in 
whole cell lysates of BMDMs from IRF3 knockout mice (f), together with their 
respective wild-type control littermates. BMDMs were either left un-stimulated or 
stimulated with 100ng/ml LPS for the indicated times. Gene expression data were 
normalized to Gapdh and are expressed relative to the levels observed in un-stimulated 
wild-type control cells. Data shown in (a-d) are presented as the mean ± SD of duplicate 
determinations from one independent experiment of at least three conducted. Data shown 
in (e, f) are representative of at least two independent experiments. WT, wild-type. KO, 
knockout. N.D. not detected. 
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3.4 IL-27p28 modulates IRF7 expression by regulating constitutive IFN-β signaling 
and promotes IFN-β responses to LPS in macrophages but not DCs 
Having determined that IL-27p28 is essential for robust IFN-β responses in endotoxin-
challenged macrophages, we next assessed whether the inability of IRF7- and IRF3-null 
macrophages to amplify IFN-β production could be due to impaired IL-27p28 synthesis. 
However, IL-27 production in response to LPS was only modestly decreased in IRF7-null 
BMDMs (~80% of wild-type levels) and only partially decreased in IRF3-null BMDMs 
(~50% of wild-type levels; Fig. 16a, 16b). Indeed, LPS-stimulated IL-27 production is 
also reduced to ~30% of wild-type levels in IRF1-deficient BMDMs176, which exhibit 
normal IFN-β transcription and secretion (Fig. 15a, 15b, 16c). Low-level production of 
IL-27p28 thus appears sufficient to support IFN-β induction in BMDMs, so we next 
assessed whether the involvement of IRF7 and IRF3 in TLR4-activated IFN-β synthesis 
occurs downstream of IL-27p28 production and signaling. Resting wild-type 
macrophages constitutively express IRF3137, and IL-27p28-knockout BMDMs express 
comparable levels of IRF3 to wild-type BMDMs (Fig. 16d). Surprisingly, we observed 
that resting wild-type macrophages displayed high levels of IRF7 mRNA and protein; in 
contrast, expression of IRF7 transcript and protein were significantly reduced in 
macrophages lacking IL-27p28 (Fig. 16e, 17a-c). These data implicated IRF7 in the IL-
27p28-driven amplification of IFN-β responses in LPS-challenged macrophages. 
Numerous studies have suggested that basal expression of IRF7 depends on 
constitutive IFN-β-ISGF3 signaling136-138,198. We observed that basal IRF7 mRNA and 
protein levels were significantly reduced in IFNAR1-deficient, STAT1-deficient and 
STAT2-mutant BMDMs, but not in MyD88-, TRIF- or IRF3-null BMDMs (Fig. 17d, 
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17e). These data not only are in line with the previous studies but also led us to 
hypothesize that there might be an endogenous IFN-β produced in macrophages to 
maintain constitutive IRF7 level via canonical IFNAR1-ISGF3 pathway. Furthermore, 
IL-27p28-knockout BMDMs exhibit reduced basal expression of total STAT1138,198,219 
(Fig. 10c), and impaired constitutive IRF7 levels. We performed chromatin 
immunoprecipitation (ChIP) experiments and detected constitutive STAT1 association at 
the IRF7 enhancer in resting wild-type macrophages, but not in IFNAR1-deficient or IL-
27p28-knockout BMDMs220 (Fig. 18a). Therefore, we further hypothesize that in resting 
state, endogenous IL-27p28 induce endogenous IFN-β to stimulate STAT1 production 
and activation which translocate to the nucleus, binding on IRF7 enhancer and calibrating 
the basal level of constitutive IRF7.  
To prove this hypothesis, we checked the IFN-β resting state level in different 
mutants and wild-type, there is no detectable IFN-β protein level (Fig. 7b) which is 
consistent with other studies136,137,139-141. However, we found constitutive levels of  IFN-β 
transcript expression in wild-type BMDMS  and the IFN-β transcription were also 
relatively unchanged in resting-state MyD88-, TRIF-, IRF3- and IRF7-null BMDMs 
compared to wild-type (Fig. 18b). These data indicated that constitutive IFN-β production 
regulates basal expression of IRF7, which plays a role downstream of IFN-β-ISGF3 
signaling. Further examination of IL-27p28-knockout BMDMs revealed that IFN-β 
transcript levels were significantly lower in these cells compared with wild-type control 
cells (Fig. 18b), supporting the concept that constitutive IFN-β production is regulated by 
IL-27p28 and impacts on basal expression of IRF7. Together, these data indicated that 
IL-27p28 enhances constitutive IFN-β production and signaling to facilitate high levels of 
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IRF7 expression in resting macrophages, which is required to achieve robust IFN-β 
production in LPS-stimulated macrophages, via direct STAT1 recruitment to the IRF7 
enhancer. 
IFN-β gene induction in LPS-stimulated DCs was abolished in IRF3-null cells but 
retained in IRF7-null cells (Fig. 19a-c)115,207, whereas macrophage IFN-β responses 
employed both IRF3 and IRF7 (Fig. 13c-f). Thus, it is very likely that the mechanism we 
found in macrophages is specific for macrophages but not DCs. This brings about the 
question regarding why the macrophages require such a mechanism to be in place for 
IFN-β production? Numerous studies have reported that macrophages produce higher 
level of IFN-β than mDCs/cDCs as well as higher in the responsiveness to type I 
IFN138,221-223. In agreement with these studies, we also found that even before any 
stimulation, the resting state IFN-β transcription level is significantly lower in BMDCs 
compared to BMDMs (Fig. 19d). Furthermore, BMDMs produce remarkable higher 
levels of IFN-β mRNA and protein compared to in BMDCs upon LPS challenge (Fig. 
19e, 19f). 
Intriguingly, basal production of IL-27p28 was reduced in BMDCs compared 
with BMDMs (Fig. 20a), suggesting that comparatively weak constitutive signaling via 
IL-27p28 could contribute to the diminished IFN-β expression observed in BMDCs 
compared with BMDMs. Followed by that, we also observed that wild-type bone 
marrow-derived DCs (BMDCs) express IRF7 mRNA transcripts and protein at only trace 
levels, in contrast to the high levels detected in BMDMs, whereas IRF3 protein is 
markedly expressed in both cell types (Fig. 20b-f). While production of both IRF7 and 
IFN-β was curtailed in BMDCs (Fig. 19e, 19f) with and without the challenge of LPS, 
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the data that IRF7 only plays a role for IFN-β production in BMDMs highlight that the 
constitutive IL-27p28-IFN-β signaling calibrates the amount of IRF7 in the resting stage 
of macrophages to provide a better response upon LPS rapidly and robustly. However, 
this mechanistic role of IRF7 was not observed in DCs. This was further supported by the 
observation that both IL-27p28 and IFNAR1 do not contribute to the LPS induced IFN-β 
in DCs. The efficiency of IFN-β induction in LPS-stimulated BMDCs was generally 
comparable between IL-27p28-knockout and wild-type cells (Fig. 21a, 21b), in contrast 
to the critical requirement for IL-27p28 in mediating IFN-β responses in endotoxin-
challenged macrophages (Fig. 9b, 9c). Indeed, IFN-β induction after LPS exposure was 
independent of autocrine/paracrine type I IFN signaling in BMDCs (Fig. 21c, 21d). 
Next, we asked whether the weak IFN-β production can be rescued by raising the 
constitutive IRF7 level in BMDCs or some mutant BMDMs (e.g. IL-27p28-knockout.). 
Pretreatment with IFN-α cytokine for 12h prior to LPS exposure induced BMDC up-
regulation of IRF7 protein and increased IFN-β secretion to levels comparable with 
untreated wild-type macrophages (Fig. 22a, 22b). The ability of IFN-α cytokine to 
enhance IFN-β responses in LPS-stimulated BMDCs required IRF7, since this effect was 
not observed in IRF7-null BMDCs (Fig. 22b). On the other hand, we pretreated IL-
27p28-knockout BMDMs with a very low dosage of recombinant IFN-β as long as the 
concentration is sufficient to raise IRF7 and trigger STAT1 activation (Fig. 22c) (the 
dosage of recombinant IFN-β used is below the detection of our ELISA kit so that we can 
easily interpret the outcome) for 5h followed by treating them with LPS. As we predicted, 
IFN-β in BMDMs lacking IL-27p28 can be increased to a comparable level to the wild-
type BMDMs regardless of mRNA level or protein level (Fig. 22d, 22e). Interestingly, 
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we couldn’t achieve the similar rescue result on IRF7-knockout BMDMs (Fig. 22f). 
Moreover, we observed that the level of IFN-β can be further raised with the increment of 
constitutive IRF7 even in wild-type BMDMs(Fig. 22d-f).      
Together, these data suggested that IL-27p28-IRF7 signaling is a cell-type 
specific positive regulator of IFN-β production in macrophages, but not in bone marrow-
derived DCs, in which weak constitutive signaling via IL-27p28-IFN-β and negligible 




 Fig.16. LPS induced IL-27 production does not require both IRF3 and IRF7 whereas IL-
27p28 may contribute to IRF7 expression in resting macrophages  
(a-c) ELISA analysis of IL-27 protein expression in cell culture supernatants of BMDMs 
from IRF7 knockout mice (a), IRF3 knockout mice (b), and IRF1 knockout mice (c), 
together with their respective wild-type control littermates. BMDMs were stimulated or 
not with 100ng/ml LPS for the indicated times. (d) Western immunoblot analysis of IRF3 
protein expression in whole cell lysates of BMDMs from IL-27p28 knockout mice 
compared with wild-type control littermates. BMDMs were either left un-stimulated or 
stimulated with 100ng/ml LPS for the indicated times. Panels (e) Real-time PCR analysis 
of Irf7 gene expression in BMDMs from IL-27p28 knockout mice compared with wild-
type control littermates. Gene expression was normalized to Gapdh and is presented as 
fold decrease from wild-type levels at each time-point. BMDMs were stimulated or not 
with 100ng/ml LPS for the indicated times. Data shown in (a-c, e) are presented as the 
mean ± SD of duplicate determinations from one independent experiment of at least three 






Fig.17. Constitutive signaling of IL-27p28 and IFN-β sustains IRF7 expression in resting 
macrophages.  
(a-b) Real-time PCR analysis of Irf7 gene expression in BMDMs from IL-27p28 
knockout mice compared with wild-type control littermates. BMDMs were left un-
stimulated (a) or were stimulated with 100ng/ml LPS (b) for the indicated times. (c) 
Western immunoblot analysis of IRF7 protein expression in whole cell lysates of 
BMDMs from IL-27p28 knockout mice together with their respective wild-type control 
littermates. BMDMs were left un-stimulated or were stimulated with 100ng/ml LPS for 
the indicated times. (d) Real-time PCR analysis of Irf7 gene expression in resting 
BMDMs from STAT2 mutant mice, and MyD88, TRIF, IRF3, IFNAR1 and STAT1 
knockout mice compared with wild-type control littermates. (e) Western immunoblot 
analysis of IRF7 protein expression in whole cell lysates of resting BMDMs from 
MyD88, TRIF, IFNAR1 and STAT1 knockout mice together with their respective wild-
type control littermates. Gene expression data were normalized to Gapdh and are 
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expressed relative to the levels observed in un-stimulated wild-type control cells. Data 
shown in (b, c, i) are presented as the mean ± SD of duplicate determinations from one 
independent experiment of four conducted (b), or two conducted (c, i). Data shown in (a) 
are presented as the mean ± SEM of at least three independent experiments (*p<0.05 by 
one-way ANOVA). Data shown in (f, h) are presented as the mean ± SEM of at least 
three independent experiments (*p<0.05 by one-way ANOVA). Data shown in (d, e, g) 
are representative of at least two independent experiments. WT, wild-type. KO, 
knockout. N.D. not detected. 
 
 
Fig.18. IL-27p28 and IFN-β sustains IRF7 expression in resting macrophages in a stat1 
dependent manner.  
(a) Real-time PCR analysis of Irf7 gene expression in resting BMDMs from MyD88, 
TRIF, IRF3, and IL-27p28 knockout mice compared with wild-type control littermates. 
(b) ChIP analysis of STAT1 binding at the IRF7 enhancer in resting BMDMs from 
STAT1, IFNAR1 and IL-27p28 knockout mice compared with wild-type control 
littermates. ChIP-enriched DNA is presented as a percentage of input DNA. (c) Real-time 
PCR analysis of Ifnb1 gene expression in resting BMDMs from MyD88, TRIF, IRF3, 
IRF7 and IL-27p28 knockout mice compared with wild-type control littermates. Gene 
expression data were normalized to Gapdh and are expressed relative to the levels 
observed in un-stimulated wild-type control cells. Data shown are presented as the mean 
± SEM of at least three independent experiments (*p<0.05 by ratio paired t test). WT, 





 Fig.19. BMDCs produce much lower IFN-β compared to BMDMs in response to LPS.  
Analysis of IFN-β gene and protein expression by real-time PCR and ELISA analysis of 
cell culture supernatants in BMDCs from IRF7 knockout mice (a, b), and IRF3 knockout 
mice (c), together with their respective wild-type control littermates. BMDCs were 
stimulated or not with 100ng/ml LPS for the indicated times. Ifnb1 expression was 
normalized to Gapdh and is expressed relative to the levels observed in un-stimulated 
wild-type control cells. (d) Real-time PCR analysis of Irf7 gene expression in un-
stimulated wild-type BMDMs and BMDCs. Gene expression was normalized to Gapdh. 
(e, f) Analysis of IFN-β gene and protein expression by real-time PCR and ELISA 
analysis of cell culture supernatants in wild-type BMDMs and BMDCs. Cells were 
stimulated or not with 100ng/ml LPS for the indicated times. Gene expression was 
normalized to Gapdh (left axis: fold induction in BMDMs; right axis: fold induction in 
BMDCs). Data shown in (a-c, g, h) are presented as the mean ± SD of duplicate 
determinations from one independent experiment of at least three conducted. Data shown 
in (d) are presented as the mean ± SEM of at least three independent experiments 





Fig.20. Poor IFN-β responses in LPS-challenged mDCs are associated with weak IL-
27p28-IFN-β signaling and negligible IRF7 expression in the steady-state.  
(a,b) Real-time PCR analysis of Ifnb1 (a)and Il27 (b)gene expression in un-stimulated 
wild-type BMDMs and BMDCs. Gene expression was normalized to Gapdh. (c, d) Real-
time PCR analysis of Irf7 gene expression in wild-type BMDMs and BMDCs stimulated 
or not with 100ng/ml LPS for the indicated times. Gene expression was normalized to 
Gapdh (c), or presented as fold decrease from BMDM expression levels at each time-
point (d). (e) Western immunoblot analysis of IRF7 protein expression in whole cell 
lysates of resting BMDMs and BMDCs that were left un-stimulated or stimulated with 
100ng/ml LPS for the indicated times. (f) Western immunoblot analysis of IRF3 protein 
expression in whole cell lysates of resting BMDMs and BMDCs that were left un-
stimulated or stimulated with 100ng/ml LPS for the indicated times.  Data shown in (a, b, 
c, d) are presented as the mean ± SD of duplicate determinations from one independent 
experiment of at least three conducted. Data shown in (e, f) are representative of at least 





 Fig.21. IL-27p28 and IFNAR1 are not required for mDCs to produce optimal IFN-β upon 
LPS stimulation.  
Analysis of IFN-β gene and protein expression by real-time PCR and ELISA analysis of 
cell culture supernatants in BMDCs from IL-27p28 knockout mice (a, b), and IFNAR1 
knockout mice (c, d), together with their respective wild-type control littermates. BMDCs 
were stimulated or not with 100ng/ml LPS for the indicated times. Ifnb1 expression was 
normalized to Gapdh and is expressed relative to the levels observed in un-stimulated 
wild-type control cells. Data shown are presented as the mean ± SD of duplicate 
determinations from one independent experiment of at least three conducted. WT, wild-






Fig.22. Exogenous type I IFN added in resting stage is sufficient to rescue low IFN-β in 
LPS-challenged mDCs and IL-27p28 deficient BMDMs.  
(a) Western immunoblot analysis of IRF7 and IRF3 protein expression in whole cell 
lysates of wild-type BMDMs and BMDCs treated or not with 500U/ml recombinant 
murine IFN-α for 12h. (b) ELISA analysis of IFN-β protein expression in cell culture 
supernatants of wild-type BMDMs, wild-type BMDCs, and IRF7 knockout BMDCs. 
Cells were treated or not with 500U/ml recombinant murine IFN-α for 12h and then 
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stimulated with 100ng/ml LPS for 6h. (c) Western immunoblot analysis of IRF7, 
phosphor-STAT1 and STAT1 protein expression in whole cell lysates of wild-type 
BMDMs treated or not with indicated concentration of recombinant murine IFN-β for 5h. 
(d) ELISA analysis of IFN-β protein expression in cell culture supernatants of wild-type 
BMDMs, IL-27p28 knockout BMDMs. Cells were treated or not with 1U/ml 
recombinant murine IFN- β for 5h and then stimulated with 100ng/ml LPS for 2 or 6h.(e) 
Real-time PCR analysis of IFN-β protein expression in cell culture supernatants of wild-
type BMDMs, IL-27p28 knockout BMDMs. Cells were treated or not with 1U/ml 
recombinant murine IFN- β for 5h and then stimulated with 100ng/ml LPS for 2 or 6h. (f) 
Real-time PCR analysis of IFN-β protein expression in cell culture supernatants of wild-
type BMDMs, IRF3 knockout, IRF7 knockout and IRF3-IRF7 double knockout BMDMs. 
Cells were treated or not with 1U/ml recombinant murine IFN- β for 5h and then 
stimulated with 100ng/ml LPS for 2 or 6h. Data shown in (b, d-f) are presented as the 
mean ± SD of duplicate determinations from one independent experiment of at least three 
conducted. Data shown in (a, c) are representative of at least two independent 





3.5 IL-27p28 regulate IFN-β in resting stage macrophages via a Pu.1 dependent 
manner 
PU.1 (also known as Spi1) is a member of the E26-transformation-specific (Ets) family 
of transcription factors and another essential partner required for the development of 
macrophages. Mice deficient in PU.1 lack both B cells and monocytes224 and high levels 
of PU.1 expression favors the development of monocytes over granulocytes225. The 
increased PU.1 levels are driven transcriptionally by C/EBPα and IRF8/ ICSBP226-229. 
Macrophages are known to require high-level expression of PU.1 for their differentiation 
from hematopoietic progenitors, whereas B cell development requires only intermediate 
expression of PU.1230,231. In our lab we have previously demonstrated that IRF8 
synergizes with PU.1 to enhance IFN-β responses in LPS-challenged human 
monocytes61. In the study, Li and et al. discovered that Pu.1 constitutively bound on IFN-
β promoter of human monocytes. Besides, they also found that LPS induced IFN-β was 
impaired after knocking down the Pu.1 expression in human monocytes, suggesting that 
the constitutive binding of Pu.1 might be functionally regulating IFN-β induction61.  
 Based on these findings, we hypothesize that Pu.1 also binds constitutively on 
IFN-β promoter of macrophages and the binding might be mediated via the resting state 
IL-27p28 signal. Indeed, we are able to show that Pu.1 constitutively bound to the 
promoter of IFN-β in wild-type BMDMs (Fig. 23a) and interestingly, the binding was 
lost in IL-27p28-knockout BMDMs(Fig. 23a). Next, we overexpressed Pu.1 on BMDMS 
and found that IFN-β transcription increased without LPS stimulation (Fig. 23b). 
However, the total Pu.1 protein level was not impaired in IL-27p28-null BMDMs 
compared to wild-type, indicating that the decrease of binding on IFN-β promoter is not 
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because of the the lower level of protein level in the mutant. We hypothesize that 
constitutive IL-27p28 provide  signals to activate Pu.1 nuclear translocation or promote 
the binding activity on IFN-β promoter.  Further studies have to be done to determine it. 
Besides, we overexpressed Pu.1 on Human HEK293 and found that IFN-β luciferase 
activity significantly increased (Fig. 23d) which in agreement to the results in murine 
immune cells. 
 Taken together, these data indicate that IL-27p28 constitutively activate Pu.1 to 




 Fig.23. Constitutive IL-27p28 activates Pu.1 to bind on the promoter and produce IFN-β 
in resting state macrophages.  
(a) ChIP analysis of Pu.1 binding at the IFN-β promoter in resting BMDMs from IL-
27p28 knockout mice compared with wild-type control littermates. ChIP-enriched DNA 
is presented as a percentage of input DNA. (b) Ifnb1 gene expression in wild-type 
BMDMs transfected with PU.1 plasmid or mock plasmid t prior to assessment of Ifnb1 
mRNA levels by real-time PCR. (c) Western immunoblot analysis of Pu.1 protein 
expression in whole cell lysates of wild-type and IL-27p28-knockout BMDMs treated 
with or without LPS for 1h. (d) PU.1 expression plasmid or mock plasmid was 
transfected into HEK293 cells before IFN-β promoter activation was quantified by 
luciferase activity. Gene expression data were normalized to Gapdh and are expressed 
relative to the levels observed in un-stimulated wild-type control cells. Data shown in (a, 
b, d) are presented as the mean ± SD of duplicate determinations from one independent 
experiment of at least three conducted. Data shown in (c) are representative of at least 




3.6 IRF7-IFN-β signaling promotes type I IFN responses to endotoxin exposure in 
vivo 
We next sought to determine whether the novel IL-27p28-IFNβ-IRF7 signaling axis 
identified in our experiments had functional consequences for host responses to 
endotoxin exposure in vivo. We therefore used a murine model of endotoxin shock that is 
known to depend on type I IFN responses to bacterial LPS to assess the requirement for 
IRF7 in supporting IFN-β production in vivo. Serum levels of IFN-β and IFN-α cytokines 
were below the limit of detection in IRF7–/– or IRF3–/– mice that had been challenged 
with LPS via the intra-peritoneal route (p<0.05 compared with WT mice; Figure 24), 
indicating that IFN-β responses in TLR4-activated macrophages require the ‘master 
regulator’ IRF7 as well as the transcription factor IRF3 both in vitro and in vivo. 
Moreover, both IRF7–/– and IRF3–/– mice exhibited improved survival after challenge 
with LPS when compared with WT animals (n=21, p<0.05; Figure 4), consistent with 
previous reports that type I IFN-mediated signals can contribute to LPS-induced toxicity 
198,207,210. Having this data, we understand that the maximal IFN-β that produced via IRF7 
dependent mechanism in macrophage indeed contribute to the patho-physiological 
significance in LPS-challenged in vivo setting. We next asked whether in vitro we can 
also demonstrate the biological function of higher level of LPS induced IFN-β in 




 Fig.24. IRF7 facilitates type I IFN responses to LPS in vivo. 
(a-b) ELISA analysis of IFN-α and IFN-β cytokine levels in serum from IRF7 KO mice 
or IRF3 KO mice compared with WT control littermates 3h after i.p. injection of 30μg/g 
LPS in sterile PBS (n=7 mice in A, n=4 mice in B; p<0.05 compared with WT mice by 
one-way ANOVA). (c) Survival of IRF7 KO mice and IRF3 KO mice compared with 
WT control littermates following i.p. injection of 30μg/g LPS in sterile PBS (n=21 mice; 
p<0.05 compared with WT littermates). Data shown in (a-b) are presented as mean ± 




3.7 IL-27p28-dependent production of IFN-β is required for maximal IL-10 
production and STAT3-mediated suppression of pro-inflammatory responses in 
LPS-stimulated macrophages 
IL-10 is an anti-inflammatory cytokine that suppresses inflammatory responses by 
macrophages and DCs during infection190. IL-10 production by LPS-stimulated 
macrophages has been reported to depend on type I IFN182,188, and we confirmed that 
LPS-induced IL-10 expression is substantially decreased in IFNAR1-knockout, STAT1-
deficient and STAT2-mutant BMDMs (Fig. 25a-h), as well in IL-27p28-knockout 
BMDMs (Fig. 26a, 26b). However, that is not a surprise because ISGF3 are downstream 
of IFNAR1 while all of these mutant BMDMs have IFN-β defect upon LPS (Fig. 8a-f, 
9b-c).  
STAT3 has been reported to be required for T cell production of IL-10 in 
response to IL-27 stimulation180, but in our assays, STAT3-deficient BMDMs exhibited 
unchanged or even enhanced IL-10 responses (Fig. 26c, d). Collectively, these data 
indicated a critical role for IL-27p28 in the regulation of IL-10 expression in TLR4-
stimulated macrophages and confirmed a contribution from type I IFN/ISGF3 signaling 
but indicated no requirement for STAT3. Previous studies have shown that IL-10 
suppresses the expression of pro-inflammatory cytokines including TNF-α, IL-6, and IL-
12p40 via effects on STAT3190. Accordingly, Western immunoblots revealed that STAT3 
phosphorylation was blunted after LPS stimulation in IL-27p28-knockout BMDMs 
despite normal STAT3 expression levels (Fig. 26e), consistent with the concept that IL-
27-driven synthesis of IL-10 cytokine occurs upstream of sustained STAT3 
phosphorylation. Furthermore, IL-27p28-knockout BMDMs and STAT3-deficient 
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BMDMs all displayed augmented TNF-α, IL-6, and IL-12p40 cytokine responses to 
endotoxin exposure when compared with wild-type BMDMs (Fig. 26f, 26g). Together, 
these data indicated that macrophages lacking IL-27p28 is characterized by decreased IL-
10 production, impaired STAT3 activation, and enhanced pro-inflammatory responses to 
LPS.  
Our data indicated that IL-27p28 is required for IFN-β induction in TLR4-
stimulated macrophages, and that STAT3 is dispensable for IL-10 synthesis in LPS-
challenged macrophages. We therefore sought to determine whether IL-27p28 effects on 
macrophage production of IL-10 are attributable to the intermediary functions of IFN-β. 
Indeed, addition of exogenous IFN-β effectively restored IL-10 responses to LPS in IL-
27p28-deficient BMDMs (Fig. 27a), suggesting that there is no obligate requirement for 
IL-27 in mediating this response. Based on this result, we wonder revert the 
overwhelming pro-inflammatory cytokines response upon LPS in IL-27p28-deficient 
BMDMs by this intervention. Before we performed that intervention, we tried to use 
exogenous recombinant IL-10 to rescue TNF-α, IL-6, and IL-12p40 cytokine upon 
endotoxin exposure in BMDMs lacking IL-27p28 and we successfully dampened the 
responses (Fig. 27b). 
Then by using the exogenous recombinant IFN-β treatment, LPS-stimulated IL-
27p28-deficient BMDMs not only are restored in IL-10 synthesis, but also returned 
STAT3 phosphorylation to wild-type levels (Fig. 28a), and decreased pro-inflammatory 
mediator (TNF-α, IL-6, and IL-12p40 as representatives) concentrations in the culture 
supernatants (Fig. 28b) which achieve comparable efficiency to co-treatment with IL-10 
and LPS (Fig. 27b). 
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From literature we know that macrophages produced IL-10 in LPS exposure is 
mediated by IFN-β182,188, so that we observed LPS induced IL-10 in IL-27p28-null 
BMDMs is impaired and the decrease is reversible by exogenous IFN-β. Based on our 
data we understand BMDCs produce much lower constitutive and LPS induced IFN-β 
(Fig. 19d-f), we wonder what the level of IL-10 in LPS challenged DCs is and we 
hypothesized that it should be consistent with lower IFN-β level. 
 Indeed, the relatively weak constitutive IL-27p28-IFN-β signaling in BMDCs 
was associated with restraint of both basal and LPS-stimulated IL-10 expression 
compared with BMDMs (Fig. 29a-c). Further analyses revealed that BMDCs exhibit little 
STAT3 phosphorylation compared with BMDMs (Fig. 19e), and release higher quantities 
of TNF-α, IL-6, and IL-12p40 after LPS exposure (Fig. 19f) which is in line with the 
current opinion and concept in the field232.  
Because our earlier observations had indicated that BMDCs from IL-27p28-
deficient mice exhibited essentially normal IFN-β responses to LPS, we next assessed 
whether IL-27p28 could promote IL-10 production in LPS-stimulated BMDCs. However, 
consistent with our earlier observation that LPS-induced IFN-β production is not 
substantially altered by IL-27p28 deficiency (Fig. 21a, 21b, 30f), we observed that IL-10 
secretion by LPS-challenged BMDCs was comparable in both IL-27p28-deficient and 
wild-type cells (Fig. 30e). These data indicated that unlike BMDMs, TLR4-mediated IL-
10 induction in BMDCs does not require IL-27p28.  
Together, these data suggested that IL-27p28-mediated production of IFN-β 
augments IL-10 expression in macrophages but not in DCs (Fig.30c, 30f ), and that this 
IL-10 production is required to promote STAT3 activation and suppress pro-
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inflammatory macrophage responses to LPS DCs (Fig.30a, 30d ). We propose that the 
different mechanisms which tightly control IFN-β regulation in between macrophages 
and DCs not only result in different levels of IFN-β induction but also direct  IL-10 and 
it’s downstream STAT3 mediated suppression of pro-inflammatory cytokines, resulting 
in unique yet overlapping characteristics for these two otherwise different cells 
population in innate immunity. The “high and low” of IL-10 in between macrophages and 
DCs define the “low and high” of pro-inflammatory cytokines which complement each 
other in the immune response and also control each other for the imbalanced responses.  
IL-27p28-IFN-β signaling pathway might be one of the “switches” for the fine-tuning of 




 Fig.25. Macrophage IL-10 responses require type I IFN signaling mediated by ISGF3.  
(a, b) Analysis of IL-10 gene and protein expression by real-time PCR and ELISA 
analysis of cell culture supernatants in wild-type BMDMs stimulated or not with 
100ng/ml LPS for the indicated times. Analysis of IL-10 gene and protein expression by 
real-time PCR and ELISA analysis of cell culture supernatants in  BMDMs from 
IFNAR1 knockout mice (c, d), STAT1 knockout mice (e, f), and STAT2 mutant mice (g, 
h), together with their respective wild-type control littermates. BMDMs were stimulated 
or not with 100ng/ml LPS for the indicated times. Il10 expression was normalized to 
Gapdh and is expressed relative to the level observed in un-stimulated wild-type control 
cells. Data are presented as the mean ± SD of duplicate determinations from one 







Fig.26. IL-27p28 production and signaling is required for maximal IL-10 expression and 
STAT3-mediated anti-inflammatory responses in macrophages.  
Analysis of IL-10 gene and protein expression by real-time PCR and multiplex analysis 
of cell culture supernatants in BMDMs from IL-27p28 knockout mice (a, b), and STAT3 
knockout mice (c, d), together with their respective wild-type control littermates. 
BMDMs were stimulated or not with 100ng/ml LPS for the indicated times. Il10 
expression was normalized to Gapdh and is expressed relative to the levels observed in 
un-stimulated wild-type control cells. (e) Western immunoblot analysis of phospho-
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STAT3 and total STAT3 protein expression in whole cell lysates of BMDMs from IL-
27p28 knockout mice together with the respective wild-type control littermates. BMDMs 
were stimulated or not with 100ng/ml LPS for the indicated times. (f, g) Multiplex 
analysis of TNF-α, IL-6 and IL-12p40 cytokines in cell culture supernatants of BMDMs 
from IL-27p28 knockout mice (f), and STAT3-knockout mice (g), together with their 
respective wild-type control littermates. BMDMs were stimulated or not with 100ng/ml 
LPS for 12h or 24h. Data shown in (a-d, f-g) are presented as the mean ± SD of duplicate 
determinations from one independent experiment of three conducted. Data shown in (e) 
are representative of at least two independent experiments. WT, wild-type. KO, 




 Fig.27. IFN-β cytokine enhances IL-10 production and STAT3-mediated anti-
inflammatory responses in IL-27p28-deficient macrophages.  
(a) Multiplex analysis of IL-10 production in cell culture supernatants of BMDMs from 
IL-27p28 knockout mice together with their respective wild-type control littermates. 
BMDMs were treated or not with 100ng/ml LPS either alone or in combination with 
250U/ml recombinant murine IFN-β for 12h or 24h. (b) Multiplex analysis of TNF-α, IL-
6 and IL-12p40 production in cell culture supernatants of BMDMs from IL-27p28 
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knockout mice compared with wild-type control littermates.,BMDMs were treated or not 
with 100ng/ml LPS either alone or in combination with 10ng/ml recombinant murine IL-
10 for 12h or 24h. (c) BMDMs from IL-27p28 knockout-mice was assessed for phospho-
STAT3 and total STAT3 protein expression by Western immunoblot analysis of whole 
cell lysates (c), and production of TNF-α, IL-6 and IL-12p40 cytokines by multiplex 
analysis of cell culture supernatants (d). BMDMs were treated or not with 100ng/ml LPS 
either alone or in combination with 250U/ml recombinant murine IFN-β for 1-3h (c), or 
12h or 24h. Data shown in (a-b, d) are presented as the mean ± SD of duplicate 
determinations from one independent experiment of at least three conducted. Data shown 
in (c) are representative of at least two independent experiments. WT, wild-type. KO, 

























Fig.28. Macrophages produce more IL-10 and STAT3-mediated anti-inflammatory 
responses than DCs.  
Analysis of IL-10 gene and protein expression by real-time PCR and multiplex analysis 
of cell culture supernatants in wild-type BMDMs and BMDCs (a-c). Cells were 
stimulated or not with 100ng/ml LPS for the indicated times. Gene expression was 
normalized to Gapdh (left axis: fold induction in BMDMs; right axis: fold induction in 
BMDCs). (d) Western immunoblot analysis of phospho-STAT3 and total STAT3 protein 
expression in whole cell lysates of wild-type BMDCs compared with wild-type BMDMs. 
Cells were stimulated or not with 100ng/ml LPS for the indicated times. (e) Multiplex 
analysis of TNF-α, IL-6 and IL-12p40 cytokines in cell culture supernatants of wild-type 
BMDCs compared with wild-type BMDMs. Cells were stimulated or not with 100ng/ml 
LPS for 12h or 24h. Data shown in (b-c, e) are presented as the mean ± SD of duplicate 
determinations from one independent experiment of at least three conducted. Data shown 
in (d) are presented as the mean ± SEM of at least three independent experiments 
(*p<0.05 by ratio paired t test). Data shown in (d) are representative of at least two 
independent experiments. WT, wild-type. KO, knockout. N.D. not detected. 
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 Fig.29. Summary: IL-27p28 enhances type I IFN and the downstream responses to LPS 
in macrophages but not DCs.  
BMDMs and BMDCs from IL-27p28 KO mice and their WT control littermates were 
stimulated or not with 100ng/ml LPS for 12h or 24h and then analyzed for production of 
cytokines TNF-α, IL-6, IL-12p40, IL-10 and IFN-β by ELISA. Data are presented as 
mean ± SD of duplicate determinations from one independent experiment of at least three 




 Fig.30. Schematic diagram summarizing our data.  
Here we present evidence that IL-27p28 is a cell-type-specific regulator of IFN-β 
synthesis and IL-10 production in myeloid-lineage antigen presenting cells. In summary, 
we have identified a lineage-restricted signaling axis comprising IL-27p28/IFN-β/IRF7, 
which is constitutively active in resting macrophages but not in DCs, and serves to 
promote robust type I IFN responses, efficient production of IL-10, and restraint of 
inflammatory responses to LPS exposure. In macrophages, IL-27p28 controls constitutive 
production of IFN-β via PU.1, and enhances STAT1 activation and IRF7 expression to 
amplify IFN-β responses to LPS. However, there is no obligate requirement for IL-27p28 
in mediating the LPS-induced IL-10 response in macrophages, since IFN-β alone in the 
absence of IL-27p28 signaling is sufficient to support macrophage IL-10 induction and 
promote STAT3-mediated anti-inflammatory responses, thus changing our understanding 
of the mechanisms identified in an earlier report233. In contrast, we were further able to 
show that this novel IL-27p28-driven mechanism of type I IFN synthesis is absent in 
myeloid DCs. Intriguingly, DCs exhibit weak constitutive signaling via the IL-27p28-
IFN-β axis and lack constitutive expression of IRF7, leading to blunted IFN-β responses, 











This study defines IL-27p28 as a cell-type-specific regulator of maximal IFN-β synthesis 
and in myeloid-lineage antigen presenting cells, the optimal level of IFN-β is significant 
in both physiological and pathophysiological settings as shown in the in vitro and in vivo 
studies. In macrophages, IL-27p28, via PU.1, controls constitutive production of IFN-β 
and enhances STAT1 activation and IRF7 expression, preparing the cells to optimally 
synthesize amplified IFN-β in responses to LPS via PU.1.   
Some of the interferon stimulated genes (ISGs) are regulated by this maximal 
IFN-β production, e.g. IL-10, CXLC10, CXCL11 and CCL5 which might contribute to 
the biological significance. There is no obligatory requirement for IL-27p28 in mediating 
the LPS-induced IL-10 response in macrophages, since IFN-β alone was sufficient to 
support macrophage IL-10 induction and promote STAT3-mediated anti-inflammatory 
responses. In contrast, DCs exhibited weak constitutive signaling via the IL-27p28-IFN-β 
axis and displayed negligible IRF7 expression, leading to blunted IFN-β responses, 
reduced IL-10 production, and limited restraint on the pro-inflammatory responses to 
LPS (Fig. 29).  
These findings further illustrate the current concept of the complementary yet 
unique roles of DCs and macrophages that bridges both innate and adaptive immunity, 
shedding a new light on the role of both IL-27p28 and IFN-β in the field. Some of the 




4.2 Constitutive type I interferon 
The mechanisms featuring type I IFN gene induction have been extensively studied in 
virus-infected fibroblasts and in various leukocyte subsets including DCs106 107. Up-
regulation of type I IFN responses seem to require IRF7 in fibroblasts and IRF8 in DCs, 
which was observed by the “double-peaks” within the 24hrs kinetic profile115,191. On the 
other hand, the molecular mechanisms of type I IFN amplification by 
monocytes/macrophages in response to LPS remained poorly studied, especially the 
importance of this pathway in the maintenance of host homeostasis and regulation of 
inflammatory responses to Gram-negative bacterial infection119,121. In fact, we found that 
type I IFN secreted specifically by macrophages indeed contributed to the mortality of 
LPS induced sepsis in murine model (Fig. 24). Also, using an array of genetic loss-of-
function approaches, we demonstrated for the first time that macrophages constitutively 
express high levels of IRF7 which are maintained by constitutive IL-27p28-IFN-β 
signaling and STAT1 binding to the IRF7 enhancer. This constitutive IL-27p28 and IFN-
β prime the macrophages prior to the infection, thus determining the level of cytokines 
profiles that the cells would produce. By acting in concert with IRF3, this novel IL-
27p28-IFN-β-IRF7 signaling axis calibrates high levels of IRF7 to support amplification 
of the macrophage IFN-β response to TLR4 ligation.  
Numerous studies136,137,139-141  reported the existence of endogenous constitutive 
IFN-β in macrophages but the mechanism to regulate this resting-state- IFN-β is still 
unknown. Regulation of constitutive IFN-β induction is not dependent on transcription 
factors such as IRF3 and IRF7136 but was proposed to involve NFKB and AP-1 
instead139. From the results, we postulated that IL-27p28 triggered another transcription 
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factor, PU.1, to bind directly on IFN-β promoter which activates transcription in resting 
state (Fig. 23). Previous study had demonstrated that constitutive binding of Pu.1 on IFN-
β promoter synergizes with IRF8 to enhance IFN-β responses in LPS-challenged human 
monocytes61. Taken together, it would be interesting to unravel the signaling pathway 
how IL-27p28 increase Pu.1 activity.  We hypothesize that Pu.1 activation has close links 
with its nuclear translocation, was to be facilitated by casein kinase II 
phosphorylation234,235. Undoubtedly, we need further studies to dissect the signaling 
cascade of this endogenous IFN-β, which will prove to be crucial in clinical treatment 
one day.  
The significant biological role of the constitutive IFN-β highlighted in this study 
is in line with the current view that endogenous IFN-β is essential to maintain 
homeostasis in the physiological state141. Besides homeostasis, IFNβ also contributed to 
the control of infection like EAE as demonstrated by the exacerbation of CNS 
inflammation in both IFNAR KO and TRIF KO mice. 171. Jeremy P., et al.  not only 
showed the physiological significance of endogenous IFN-β to fine-tune the immune 
response, it also suggested that TLRs pathways may be regulated by external stimulation 
from commensals61. Hence, we can say that other than calibrating the homeostasis of 
immune system to avoid over-response, endogenous IFN-β also plays a significant role to 
better prime the immune system against virus infection. This strongly suggests that a yin-
yang system is in place to control switching from between an optimal response to 




4.3 Cell-type specific mechanism of IFN-β and the downstream response in APCs 
In this study, we also highlight the yin-yang control of IFN-β production by DCs and 
macrophages in the vicinity of infection/inflammation. The preferential ability of 
pathogens to induce an interferon response in some cells but not others is not well 
understood. Although BMM and BMDC are derived from the same BM progenitor cells, 
many studies have shown that there were significant differences in terms of type I IFN 
production and in cytokine and chemokine profiles221,236. In this study, we are able to 
summarize an unique list of signaling molecules which could possibly explain for the 
altered IFN and cytokine production by BMDM and BMDC upon LPS stimulation. (Fig. 
31). 
 
Fig.31. Macrophage-restricted role for IL27p28/IFN-β/IRF7 signaling in type I IFN 
responses to TLR4 ligation.  
The tables summarised the data in this study together with the previous reports that make 
comparison of difference and similarity of LPS induced IFN-β mechanism in between 




IRF7-, IFNAR1- and IL-27p28-knockout BMDCs have no defects in LPS induced 
IFN-β production compared to wild-type BMDCS but these three molecules play key 
roles in IFNβ production by BMDMs. Besides these 3 molecules, IRF3, Trif and Myd88 
are also involved in IFNβ production in both cell types. Gathering these information 
together, we can explain our data logically; since there is negligible levels of IRF7 in 
wild-type BMDCs (Fig. 20e), IFN-β production by wild-type BMDCs should be similar 
to the IRF7-null BMDMs and indeed it is indicated by our data. Furthermore, the 
negligible IRF7 in wild-type BMDCs is due to the negligible of constitutive IL-27p28- 
IFN-β signalling which again make IL-27p28- and IFNAR1-deficient BMDCs produce 
comparable IFN-β to wid-type BMDCs. 
Differential levels of constitutive IFN-β in macrophages and DCs consequentially 
results in different IFN-β and ISGs induction upon stimulation of these two cell types.  In 
macrophages, IL-27p28-dependent production of IFN-β drives efficient IL-10 synthesis 
and promotes STAT3-mediated, suppressing inflammatory response to LPS. In contrast, 
the lack of an IL-27p28-IRF7-IFN-β autocrine/paracrine signaling axis in DCs is 
associated with reduced IFN-β cytokine expression and comparatively weaker IL-
10/STAT3 activation upon LPS stimulation. Indeed, we observed that an impaired IL-
27p28 signaling in TLR4-stimulated macrophages led to a blunted IL-10 production, 
decreased STAT3 activation, and increased pro-inflammatory cytokines production that 
is similar to DCs response to LPS. 
In the micro-environment of the sites of inflammation and gram-negative bacteria 
infection, the unique but complementary roles of macrophages and DCs each regulate 
production of a unique set of cytokines. Our data provides a new insight of the individual 
99 
 
yet synergic contribution of DCs and macrophages in the host defense.  The most 
prominent role of DCs is the ability to roam around in the immune system and present 
antigens to naïve T cells. On the other hand, macrophages are relatively immobile with a 
tendency to stay in the peripheral tissue. Upon recognition of gram-negative bacteria,  
macrophages reside in the region produce high level of type I IFN to recruit more 
activated macrophages to perform phagocytosis 5. Upon phagocytosis, more type I IFN 
would be produced to recruit even more macrophages and this works in as a positive-
feedback loop. Furthermore, type I IFN also induces up-regulation of MHC class I 
molecules and co-stimulatory molecules74,237, thus enhancing DC maturation and 
activation 75,76. In contrast, with the production of low levels of type I IFN, high IL-12 
and IL-6 in lymphoid tissues, DCs are able to increase T cells proliferation, promote 
differentiation and polarization upon antigen-presenting to naïve T cells36,238-241. When 
both DCs and macrophages come to the vicinity of each other at the site of infection, high 
levels of type I IFN produced by macrophages subsequently triggers an auto-regulatory 
loop leading to high levels of IL-10 production from macrophages thus preventing the 
overwhelming production of pro-inflammatory cytokines. On the other hand, high levels 
of IL-12, IL-6 and TNF-α secreted by DCs will promote the cytokine production by 
macrophages to boost immunity against the pathogens. Undeniably, type I IFN is one of 
the key features that calibrate immune response and homeostasis. Thus, we would like to 
propose here that constitutive IL-27p28- IFN-β-IRF7 might be the mechanism that 
regulates the different yet complementary characteristics of the two APCs. 
Our data showed that co-treatment of recombinant IFN-β with LPS rescues the 
impairment of STAT3 activation and leads to an overwhelming response of IL-12b, IL-6 
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and TNF-α in IL-27p28-null BMDMs, comparable to that of in wild-type BMDMs. We 
postulated that this is due to the rescue of dwindling levels of IL-10 in the mutant 
BMDMs. However recent report suggested that IFN-β itself might induce Stat3 
activation, which contribute to the suppression of pro-inflammatory cytokines24. Other 
studies also proposed that IL-27 can also suppresses the function of macrophages and 
DCs by inhibiting TNF-α and IL-12 cytokine production181. Further studies are required 
to differentiate the factor that attributed to the rescue effect of recombinant IFN-β in this 
setting. 
 
4.4 IL-27 as one of the ISGs: Another role playing downstream but not upstream of 
IFN-β 
We showed that in macrophages, LPS-induced IL-27 production, amplification of IFN-β 
synthesis, and maximal IL-10 production were dependent on type I IFN signaling. This is 
likely initiated by constitutive IFN-β and early-phase release of IFN-β following 
endotoxin exposure. While amplification of IFN-β synthesis and optimal IL-10 
expression depended on IL-27p28, how increased production of IFNb is being induced by 
IL-27 upon LPS stimulation remainas an open question in this study. Using IFNAR1-
knockout BMDMs does not answer this question because type I interferon signaling 
pathway is completely abolished in the mutant. Therefore, we could not rule out the 
possibility that a low amount of IFN-β might be sufficient to induce optimal level of 
LPS-induced IL-27 production unlike IL-10 production which required maximal level of 
IFN-β. It is highly possible that different ISGs possess different thresholds for activation 
by IFN-β signaling, possibly, low levels of IL-27 is sufficient to trigger full induction of 
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IFN-β by IRF1 null BMDMs upon LPS stimulation (Fig. 15a-b, 16c). In this study, we 
provided the evidence to support that constitutive IL-27p28 regulates the production of 
IFN-β, but further studies are needed to discover the possible “cross-talk” in between 
LPS-induced IL-27 and IFN-β. The cross-talk between IL-27p28/IL-27 and IFN-β 
production may therefore represent a mechanism by which type I IFN responses can be 
fine-tuned to achieve graded transcriptional responses over the course of an infection. 
 
4.5 IRF7 and the regulation 
It is well established that IRF7 is indispensable for the operation of the IFN-β 
amplification loop in virus-infected fibroblasts, and for CpG-stimulated IFN-β induction 
in plasmacytoid DCs115,119,121, but the role for IRF7 in TLR4-IFN-β responses in 
macrophages has not previously been investigated. Plasmacytoid DCs do not express 
TLR4 and are thus unresponsive to LPS, but this population is known to constitutively 
express high levels of IRF7 that enable efficient production of type I IFN in response to 
viral infection187. Variable expression of IRF7 may therefore fine-tune the magnitude of 
the IFN-β response in different host cell lineages242. Accumulating evidence suggests that 
IRF7 expression and activity is tightly regulated at multiple levels including 
transcription243, mRNA stability244, translation245,246, and protein stability247,248.  
At the transcriptional level, the Epstein-Barr virus BRLF1 protein was shown to 
repress the transcription of IRF7 and IRF3, leading to decreased IRF7 and IRF3 mRNA 
and protein levels and therefore reduced IFN-β production 249. ATF4 is a component of 
the cellular integrated stress response that can also inhibit IRF7 transcription to reduce 
type I IFN induction 250. Interestingly, IRF7 can in turn regulate ATF4 levels and activity, 
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suggesting a cross-talk between the type I IFN response and the cellular integrated stress 
response 250. Another transcription factor, Forkhead box O3 (FOXO3) was recently 
identified as a negative regulator of Irf7 transcription. FOXO3, IRF7 and type I IFN form 
a coherent feed-forward regulatory circuit251. FOXO3–IRF7 regulatory circuit represents 
a novel mechanism for establishing the requisite set points in the interferon pathway, 
suggesting this dynamic interplay between FOXO3, IRF7 and type I IFN optimizes the 
antiviral response to achieve the appropriate balance between host defense and rampant 
inflammation251. 
IRF7 translation was recently found to be inhibited by the translational repressors 
4E-BP1 and 4E-BP2 245. Numerous post-translational modifications can regulate IRF7 
activity including; modification of IRF7 phosphorylation status and nuclear translocation 
by the EBV oncoprotein latent membrane protein-1 (LMP1) 252; polyubiquitination of 
IRF7 and subsequent proteasomal degradation by TRIM21 253; SUMO modification of 
IRF7 transcriptional activity mediated by PIAS1 254,255; and lysine acetylation effects on 
IRF7 DNA binding as mediated by p300/CREB-binding protein-associated factor 
(PCAF) and GCN5 256. Recently, TRIM28 was found to act as a IRF7-specific SUMO E3 
ligase (analogous to PIAS1), that attenuates transcriptional activity and abrogates IFN-
α1, IFN-β, and ISRE promoter activation and IFN expression 257. MafB is another 
molecule that was found to inhibit IRF7-mediated transcription by disrupting the binding 
of IRF7 to target gene promoters 258.  
 It would therefore be useful to determine the endogenous negative regulators that 
suppress IRF7 expression in cDCs, and to assess whether these restrictions are influenced 
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by IL-27p28-IFN-β signaling. A number of these candidates (e.g. FOXO3, 4E-BP1/2, 
OASL1) can be studied in the future using our LPS challenged murine APCs 
model245,246,259. 
 
4.6 Cross-talk between IRF3 and IRF7 
In the classical virus infection model in fibroblast and DCs, IRF3 forms either homo-
dimers or hetero-dimers with IRF7 after phosphorylation by TBK1/IKKi. This is 
subsequently leads to its nuclear translocation for its occupancy at the IFN-β promoter 
region to induce IFN-β expression110.  Alternatively, studies have also reported that 
constitutive IRF7 is localized in the cytoplasm and become phosphorylated by 
TBK1/IKKi to forms a homo-dimer, which  translocates into the nucleus to establish the 
IFN-β enhanceosome260,261. Based on these previous findings, it will be interesting to 
examine the role of IRF3 and IRF7 in these proposed mechanisms in this study.  
Experiments such as immunoprecipitation (IP) can be done to determine if homo-dimers 
or/and hetero-dimers of IRF3 and IRF7 are important to induce IFN-β in LPS-challenged 
cells.  
Treatment with low dosage of recombinant IFN-β on IRF3-null BMDMs 
followed by LPS stimulation managed to rescue the blunted IFN-β production to a level 
comparable to wild-type (Fig. 22f). However, defect of IFN-β production could not be 
reversed when the same treatment was performed on both IRF7-knockout and IRF3-
IRF7-double-knockout BMDMs, suggesting that IRF3’s role would be diluted when the 
macrophages have excessive level of IRF7 protein expression prior to the infection. On 
the other hand, we also showed that LPS-induced IFN-β transcription in IRF3- and IRF7-
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double deficient BMDMs was much lower than in IRF3- and IRF7- single-knockout 
BMDMs.  This data suggest that upon LPS stimulation IRF3 and IRF7 play overlapping 
but possesses unique roles in IFN-β transcription. Lacking either IRF3 or IRF7 resulted 
in decreased IFN-β transcription while double deficiency led to ablation of the IFN-β 
transcription. 
 
4.7 Regulation of IL-27 and the signaling pathway 
IL-27 can critically modulate immune responses to bacterial products173,174,182,214,262. This 
cytokine is a heterodimer composed of a specific p28 subunit (IL-27p28), and a common 
subunit of EBI3 that has been extensively studied in T lymphocytes. IL-27 signals 
through its cognate receptor complex IL-27R, which consists of a unique subunit IL-
27Rα (also known as WSX-1) and a signal transducing subunit gp130 that is shared with 
the IL-6 receptor complex 173,174. IL-27p28 expression in LPS-challenged DCs and 
macrophages was found to be dependent on both MyD88 and TRIF signaling, and 
mediated by NF‑κB c-Rel, IRF1, IRF8 and IFNAR1 signaling176-178,233,263. However, the 
role of IRF3 to regulate IL-27p28 is known in DCs but still not clearly understood in 
macrophages’ response to TLR4 ligand264. Here in this study, we will provide evidence to 
show that only IRF3 but not IRF7 is involved in the induction of IL-27 in LPS-stimulated 
macrophages. 
IRF1-null and IRF3-null BMDMs exhibited reduced IL-27 production in response 
to LPS (Fig. 16c) but displayed normal levels of IFN-β transcription and secretion (Fig. 
18a-b). LPS-induced amplification of IFN-β responses thus appears to require only low-
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level production of IL-27p28. This finding is consistent with the model proposed by us 
and many others, in which continuous, weak IFN-β signaling primes cells for rapid 
enhancement of IFN-β responses after pathogen encounter137,219. Expanding on this 
concept, we hereby proposed that resting macrophages exhibit constitutive IL-27p28-
IFN-β signaling that supports weak basal activation of molecules such as STAT1 and 
maintains the expression of target genes such as IRF7. Upon pathogen encounter, 
macrophage activation then drives mutual up-regulation of IL-27p28 and IFN-β to 
promote rapid amplification of the IFN-β response. These data support the phenotype that 
we observed in IRF1-knockout BMDMs in which a low amount of IL-27 is abundant to 
induce full induction of IFN-β upon LPS stimulation. 
Further studies still needs to be done to research the role of EBI-3 subunit and the 
IL-27R in this model. On the other hand, STAT3 is a molecule known to be downstream 
of IL-27R signaling to promote T cell production of IL-10 and to support monocyte 
expression of pro-inflammatory cytokines, Here, our data showed that IFN-β expression 
in response to LPS was increased in BMDMs lacking STAT3., therefore our data suggest 
that IL-27R signaling may not play a role in this LPS induced IFN-β in BMDMs  More 
research should be devoted to search for the specific mediators and signaling pathway 
that act downstream of this newly proposed endogenous IL-27p28 urge more research. 
 
4.8 Clinical perspective 
Together, IFN-β, IL-27 and IL-10, have been shown to shape patho-physiological 
mechanisms of several diseases. Auto-immune diseases are often associated with these 
cytokines, typically observed in Multiple Sclerosis (MS). In MS, type I IFNs exert 
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beneficial immuno-modulatory functions, and recombinant IFN-β is widely used as a 
first-line therapy to reduce the frequency and severity of relapsing-remitting MS265. It is 
thought that the therapeutic effects of IFN-β in MS patients are partly mediated by IL-27 
induction, since IL-27 suppression of Th17 development is protective in murine models 
of the disease173,174,262. The mechanisms of action of IFN-β and IL-27 therapy in MS are 
subject to ongoing investigation, but IL-27 and IL-10 have been proposed by an array of 
studies to contribute the beneficial effect of IFN-β therapy262,265-268. Thus, IFN-β, IL-27, 
and IL-10 appear to exert a range of overlapping immuno-regulatory effects in both 
human and murine Th1/Th17 inflammatory disorders268. In MS, Shinohara, M. et al. 
suggested that IFN β promote IL-27 dependent suppression of Th17 cells in EAE in 
microglia269. The idea is further strengthened in the field and proposed that it is the 
TLR4-Trif pathway induced IFN-β and ISGs like IL-10 constrains Th17 cells which 
result to the efficacy of treating the disease270. Another recent study concluded that IFN-β 
not only suppress Th17 cells via enhancing IL-27 and IL-10 of innate immune cells like 
dendritic cells, but also promote IL-10 producing CD4+ T cells89, skewing the T cells 
population. Here, we found that  that IL-10 production in macrophages is IL-27p28-
independent but still requires IFN-β. This may offer an explanation for a recent report 
that IL-27 signaling is dispensable for successful IFN-β therapy in a murine model of 
MS268. In summary, our data provide a more detailed molecular mechanism of the 
immunoregulatory role of IFN-β. More importantly, we provide possible answers to the  
poorly understood mechanism of why IFN-β is unresponsive in some MS patients.  
Our data not only fit into a LPS/ Gram-negative bacterial infection pathological 
setting but also to autoimmune diseases. This indicates that targeted modulation of IL-
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27p28 production and signaling in macrophages may provide a novel therapeutic strategy 
or improve the current strategy in clinic of other different infections and inflammatory 
conditions. Similarly in virus infection, pegylated IFN (PegIFN-α) in combination with 
the guanosine analogue Ribavirin (Rbv) is the current standard of care of patients with 
chronic hepatitis C, and treatment for selective patients with hepatitis B271,272. The role of 
IFN-α therapy in halting hepatitis progression has been well recognized, but whether 
IFN-α therapy prevents Hepatocellular carcinoma (HCC)  development in chronic 
hepatitis patients is still being debated273,274. On the other hand, the therapeutic role of 
type I IFN in GVHD and GVL after allogeneic bone marrow transplantation has been 
studied for decades 90,91, especially in relapse of chronic myeloid leukemia after bone 
marrow transplantation92. However, the mechanisms of action are still poorly studied, and 
the application still remains controversial93,94.  
In a more relevant model, type I IFN is central mediator in endotoxemia (and 
probably sepsis) which are proven by many studies. The resistance to endotoxemia can be 
induced by the deletion of genes encoding IFN-β, IFNAR1, Tyk2, or other genes 
involved in the induction of, or in the response to, type I IFN275-277. Thus, based on our 
data, neutralizing IL-27p28 or IFN-β may be considered as new therapeutic targets in 









In summary, like most cytokines, type I IFNs induce balanced responses by  activating 
signals to induce anti-pathogens states and promote immune responses that are 
counterbalanced by suppressive signals that limit toxicity to the host. These balanced 
responses are fine-tuned by host factors at multiple levels, including signaling, 
transcription, translation and cell-type specific regulation. Through highlighting the 
different IFN-β level, responses and regulation in between DCs and macrophages, we 
believe that our findings provide a novel view of the mechanism adopted in APCs that 
fine-tune IFN-β by calibrating the amount of IRF7, proposing constitutive IL-27p28- 





Chapter5: Future perspectives 
 
5.1 Signaling pathway in between IL-27p28 to Pu.1 
We discover a IL-27p28 dependent mechanism that activate Pu.1 binding on IFN-β and 
induce the transcription in resting state macrophages, therefore it would be interesting to 
further unravel the signaling pathway that IL-27p28 activates Pu.1 and its activity or 
nuclear translocation. Studying the relevance of Pu.1 phosphorylation by casein kinase II 
to undergo nuclear translocation234,235 might be one of the directions that we could 
pursue. On the other hand, synergy between IRF8 and Pu.1 have been previously 
demonstrated that to enhance IFN-β responses in LPS-challenged human monocytes 61, 
whether IRF8 also play a role in the constitutive IFN-β expression is an interesting topic 
to study especially if we can demonstrate the molecular mechanism how they act on IFN-
β promoter cooperatively. 
 
5.2 IRF7’s silence in DC 
Followed by the Foxo3 study278, that would be interesting to show that FOXO3 is 
involved and bind on IRF7 loci in BMDCs which might explain the negligible IRF7 level 
in DCs. If the involvement of FOXO3 is true, we predict to see FOXO3-null BMDCs 
producing comparable levels of  IFN-β to wild-type BMDMs while IRF7-and FOXO3-
double deficient BMDMs and BMDCs will produce similar levels of IFN-β. Meanwhile, 
other negative or positive regulators could be further studied to elucidate the complexity 
of IRF7 regulation in APCs, especially the mechanism in place in the resting state.  
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5.3 Crosstalk among Transcription factors 
In reference to Fig. 6, the possible binding sites of the individual transcription factors 
have been proposed and confirmed in murine APCs. Given that IRF3, IRF7 and Pu.1 
have been suggested to play important role of LPS-induced IFN-β in macrophages, the 
crosstalk among them in both resting and LPS challenged states are to be studied. 
 
5.4 The biological significance of the maximal IFN-β in other models 
Although we have shown the physiological and pathophysiological significance of 
maximal IFN-β of macrophages upon LPS stimulation in vivo and in vitro, it would be 
good to unravel other biological function of this mechanism or only the existence of 
endogenous IL-27p28-IFN-β axis.  Recently in an experimental autoimmune 
uveoretinitis (EAU) model, the ability of IL27p28 had been shown to inhibit both Th1 
and Th17 responses and to ameliorate not only the induction, but also the effector phase 
of EAU, bodes well for clinical usefulness of IL27p28 augmentation to control 
autoimmunity279.  This report urges us to further unravel the contribution of this 
mechanism in some of the IFN-β related disease model, such as EAE. 
 A recent report that IL-27 signaling is dispensable for successful IFN-β therapy 
in a murine model of MS268, suggesting that IL-27 may not be an effector cytokines of 
IFN-β therapy like previously reported204,205. What is the level of EAE severity and 
mortality in IL-27p28-knockout mice? May IL-27p28/IL-27 complement the IFN-β 
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therapy in murine or even in human multiple sclerosis? These all are open questions that 
we are interested to answer. 
 
5.5 IL-27 and IL-27p28 
IL-27 consists of the cytokine subunit IL-27p28 and the non-signaling α-receptor EBI3, 
whereas IL-27R consists of WSX-1 and gp130. By studying EBI3 and WSX-1-null mice, 
our preliminary data shows that IL-27 and IL-27R might not play an identical role to IL-
27p28 in response of LPS stimulation in BMDMs (data not shown). Further experiments 
have to be done to confirm these results and also to explain the possible unmatched 
phenotypes among the mutants in IL-27-IL-27R signaling pathway. Notably, the IL-
27p28 (also known as IL-30) and EBI3 are not always expressed together280,281, which 
suggests that they may have unique functions. Indeed, IL-27p28 was shown to 
additionally act via the non-signaling membrane-bound IL-6 α-receptor (IL-6R) as an 
agonistic cytokine but also as a gp130 β-receptor antagonist282 without the need of WSX-
1, suggesting the receptor of IL-27p28 can be other than IL-27R.  
On the other hand, previous study also showed that IL-27p28 is a natural 
antagonist of IL-27, indicating that their role is not similar but rather it is the opposite283. 
Therefore, if IL-27p28 role in our study is not attributed by IL-27, the receptor that 
signals to activate downstream effect resulting the activation of Pu.1 is also a question 




5.6 Rescue with recombinant IL-27 or IL-30 
One of the important but straightforward experiment is trying to rescue the IL-27p28-null 
BMDMs or wild-type BMDCs with recombinant IL-30 or IL-27 similarly to the 
experimental setting of recombinant IFN-β/α used in the rescue experiments in this study. 
Our preliminary data shows that none of both IL-30 and IL-27 manages to reverse the 
blunt IFN-β production. Undeniably, further experiments will have to be done to confirm 
this data. However, we suspect the defects caused by IL-27p28 deficiency might have 
occurred in early development of the cells which could not be easily reverted by transient 
additional cytokines treatment. Continuously culturing the IL-27p28-null cells with low 
dosage of IL-30 or IL-27 might be a possible experiment to check the reversibility of 
IFN-β impairment.  
 
5.7 The mechanism of LPS induced IFN-β in human antigen-presenting cells  
A study demonstrated that murine p28 acts as an agonistic cytokine via both murine and 
human IL-6R, indicating that p28 exhibits no species specificity282. Albeit further 
confirmation has to be made, using IL-27p28 research data to translate into human 
research which eventually contribute to potential clinical application is promising. By 
starting from human monocytes derived macrophages and DCs, we aim to do a 
translational research on understanding of the type I interferon regulation and biological 




5.8 Closing remarks 
We have identified an essential lineage-restricted signaling axis comprising IL-
27p28/IFN-b/IRF7 which is constitutively maintained in resting macrophages and is 
required to mount robust IFN responses to LPS exposure. Interestingly, this novel IL-
27p28-driven mechanism of IFN synthesis in macrophages is absent in myeloid DCs 
which lack constitutive expression of IRF7 and exhibit blunted IFN responses to LPS.  
 
Fig.32. Schematic diagram summarizing the two different cell type specific mechanisms 
of IFN-β in resting and LPS-challenged states in APCs that we proposed in this study.  
Our data concluded that a novel IL-27p28-IFNβ signaling axis marshals constitutively 
expressed IRF7 into TLR4 signaling pathways to promote the robust IFN response which 
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